joan montaner villalonga - ibis: instituto de … · curriculum vitae, joan montaner villalonga 5...

Curriculum Vitae, Joan Montaner Villalonga

1

JOAN MONTANER VILLALONGA November 2013


2

The CV in numbers Page

STUDIES and OCCUPATIONS--------------------------------------------------------------------------------------------------3

PUBLICATIONS [index h = 44] ------------------------------------------------------------------------------------------------4

ORIGINAL ARTICLES [206] -----------------------------------------------------------------------------------------------------4

REVIEW ARTICLES [32] --------------------------------------------------------------------------------------------------------25

BOOK CHAPTERS [17] ---------------------------------------------------------------------------------------------------------28

BOOKS [7] --------------------------------------------------------------------------------------------------------------------------29

INVITED PROFESSOR [67 international conferences] ------------------------------------------------------------30

ORGANIZATION of COURSES and CONGRESSES [19] -------------------------------------------------------------35

FOREIGN CENTERS STAGES [5] --------------------------------------------------------------------------------------------36

GRANTS and COMPETITIVE RESEARCH PROJECTS [24 PI] ------------------------------------------------------36

DIRECTED DOCTORAL THESIS [12] ---------------------------------------------------------------------------------------39

AWARDS [11] ---------------------------------------------------------------------------------------------------------------------40

EXTERNAL REVIEWER for JOURNALS [62] -----------------------------------------------------------------------------41

EVALUATION AGENCIES [19] -----------------------------------------------------------------------------------------------43

INTL EDITORIAL BOARDS MEMBER [5] ---------------------------------------------------------------------------------43

SCIENTIFIC SOCIETIES [12] --------------------------------------------------------------------------------------------------44

RESEARCH FOUNDATIONS [3] ---------------------------------------------------------------------------------------------44

CLINICAL TRIALS in NEUROVASCULAR DISEASES [8 PI/promotor] ------------------------------------------45

INTELECTUAL PROPERTY and PATENTS [5] ---------------------------------------------------------------------------46


3

STUDIES and OCCUPATIONS: Graduated in Medicine and Surgery at the Faculty of Medicine (Cadiz). 1988-1994 Doctorate lectures at the University of Cadiz, Spain 1995-1996 Speciality in Neurology at the Hospital General Universitario Vall d´Hebron. Barcelona, 1996-2000 Sub-speciality in Cerebrovascular Diseases at the Neurovascular Unit. Hospital General Universitario Vall d´Hebron. Barcelona, 2000-2002 Doctor in Medicine. Thesis: “The role of Matrix Metalloproteinases in the acute phase of ishemic stroke” (July 2001). Autonomous University of Barcelona (excellent cum laudem). Neurologist of the Emergency Department at the Hospital General Universitario Vall d´Hebron. Research training within the program of the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias, 2002-2004. Director of the Neurovascular Research Laboratory of the Neurovascular Unit. Vall d´Hebron Hospital. Barcelona (since 2003). Staff neurologist (teniard) since 2005. Tutor of neurology residents on training (2005-2009) Research Acreditation by the Catalan Agency for Quality of the Universitary system. 2007 Coordinator of the Neurosciences Research Area at Vall d’Hebron Hospital, VHIR 2011-2013 Director of the Stroke Programme, IBIS-HVR, Sevilla, 2013-


4

PUBLICATIONS (index H =44, index m=2.93): Original papers 1. Montaner J, Mauleón A, Vidal C, Molina C, Alvarez-Sabín J.

Ictus: Un desconocido para la población. Rev Neurol 1998;27:943-947.

2. Montaner J, Tintoré M, Falip M, Montalbán X, Codina A. Electrocución: Complicaciones neurológicas. Neurologia 1999; 14:136-137.

3. Montaner J, Alvarez-Sabín J. Opalski’s syndrome. J Neurol Neurosurg Psychiatry 1999;67:688-689.

4. Montaner J, Alvarez-Sabín J, Rovira A, Molina C, Grivé E, Codina A, Miquel F. Alteraciones del sistema arterial vertebrobasilar en pacientes con hemiespasmo facial: hallazgos mediante angio-RM. Rev Neurol 1999;29:700-703.

5. Cervera Alvarez C, Montaner Villalonga J, Espin Basany E, Falcó Ferrer V, Armengol Carrasco M, Fernández de Sevilla Ribosa T. A febrile syndrome with bacteremia. Rev Clin Esp. 1999;199:45-6.

6. Alvarez-Sabín J, Molina C, Abilleira S, Montaner J, García F, Alijotas J. “Código ictus” y tiempos de latencia en el tratamiento de reperfusión durante la fase aguda del ictus isquémico. Med Clin (Barc) 1999;113:481-483.

7. Alvarez-Sabín J, Turón J, Montaner J, Malinow R, Codina A. Homocisteina plasmática en pacientes con ataques isquémicos transitorios. Med Clin (Barc) 1999;113:531-532.

8. Molina C, Alvarez-Sabín J, Montaner J, Rovira A, Abilleira S, Codina A. Impaired cerebrovascular reactivity as a risk marker for first-ever lacunar infarction. A case-control study. Stroke 1999;30:2296-2301.

9. Montaner J, Alvarez-Sabín J, Molina C, Abilleira S, Rovira A. Parálisis pseudobulbar aguda: utilidad de las técnicas de difusión por resonancia magnética. Rev Neurol 1999;29:1181-4.

10. Abilleira S, Molina C, Bosch J, Montaner J, Codina A, Alvarez-Sabín J. Determinación de parámetros Doppler en el estudio de las venas cerebrales basales: vena basal de Rosenthal y vena cerebral media. Rev Neurol 1999;29:963-8.

11. Montaner J, Molina C, Alvarez-Sabín J, Codina A. “Herald hemiparesis” of the basilar artery occlusion. European Journal of Neurology 2000;7:91-93.

12. Sastre-Garriga J, Tintoré M, Montaner J, Rovira A, Montalbán X, Codina A. Metástasis cerebrales calcificadas. Neurología 2000;15:136-139.

13. Montaner J, Abilleira S, Molina C, Sastre-Garriga J, Alvarez-Sabín J, Codina A. “Limb-shaking” postprandial.


5

Neurología 2000;15:267-268. 14. Sastre-Garriga J, Molina C, Montaner J, Mauleón A, Pujadas F, Codina A, Alvarez-

Sabín J. Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature. European Journal of Neurology 2000;7:449-453.

15. Alvarez-Sabín J, Montaner J, Rovira A, Turón J, Molina C, Malinow R, Abilleira S, Codina A. Ausencia de correlación entre homocisteina plasmática y microangiopatía cerebral en pacientes con ataque isquémico transitorio. Rev Neurol 2000:30:606-609.

16. Rovira A, Pedraza S, Molina C, Capellades J, Grivé E, Rovira A, Montaner J, Alvarez-Sabín J. Difusión por resonancia magnética en el diagnóstico de los infartos subcorticales agudos. Rev Neurol 2000;30:914-919.

17. Molina C, Alvarez-Sabín J, Schonewille W, Montaner J, Rovira A, Abilleira S, Codina A. Cerebral microembolism in acute spontaneous internal carotid artery dissection. Neurology 2000;55:1738-1740.

18. Montaner J, Molina C, Alvarez-Sabín J, Ordi J. Manifestaciones neurológicas en la púrpura de Schönlein-Henoch: ¿vasculitis cerebral ó encefalopatía posterior reversible?. Med Clin (Barc) 2000;115:677.

19. Montaner J, Alvarez-Sabín J, Abilleira S, Molina C, Arenillas J, Codina A. Reactantes de fase aguda en el ictus: diferencias entre el infarto isquémico y la hemorragia intracerebral. Med Clin (Barc) 2001;116:54-55.

20. Montaner J, Pujadas F. Meningioma del surco olfatorio. Med Clin (Barc) 2001;116(3):120.

21. Molina C, Montaner J, Abilleira S, Ibarra B, Romero F, Arenillas J, Alvarez-Sabín J. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001;32:1079-1084.

22. Montaner J, Rio J, Codina A. Paresia del espinal: apuntes semiológicos. Neurología 2001;16:171.

23. Montaner J, Dominguez J, Molina C, Alvarez-Sabín J. Ictus y esclerodermia. ¿Raynaud cerebral?. Neurología 2001;16:236-237.

24. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, González MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke. Temporal profile and relation to neurological impairment. Stroke 2001;32:1759-1766.

25. Montaner J, Alvarez-Sabín J, Barberá G, Anglés A, Molina C, Abilleira S, Arenillas J, Chacón P, Monasterio J.


6

Correlación entre la expresión de citocinas proinflamatorias y metaloproteinasas de matriz en la fase aguda del ictus isquémico. Rev Neurol 2001;33:115-118.

26. Montaner J, Vidal C, Molina C, Alvarez-Sabín J. Selecting the target and the message for a stroke public education campaign: A local survey conducted by neurologists. Eur Journal Epidemiol 2001;17 (6): 581-586.

27. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, Monasterio J. Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001;32: 2762-2767.

28. Molina CA, Montaner J, Abilleira S, Arenillas JF, Ribó M, Huertas R, Romero F, Alvarez-Sabín J. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke. A case-control study. Stroke 2001;32: 2821-2827.

29. Arenillas J, Molina C, Montaner J, Abilleira S, González-Sánchez MA, Alvarez-Sabín J. Progression and Clinical Recurrence of Symptomatic Middle Cerebral Artery Stenosis: A Long-Term Follow-Up Transcranial Doppler Ultrasound Study. Stroke 2001;32: 2898-2904.

30. Castillo J, Dávalos A, Álvarez–Sabín J, Pumar J.M, Leira R, Silva Y, Montaner J, Kase C.S. Molecular signatures of brain injury after intracer ebral hemorrhage. Neurology 2002;58:624–629.

31. Molina CA, Alvarez-Sabín J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, Romero F, Codina A. Thrombolysis-related hemorrhagic infarction (HI1-HI 2). A marker of early reperfusion, reduced infarct size and improved outcome in patients with a proximal MCA occlusion. Stroke 2002;33:1551-1556.

32. Tellez Lara N, Montaner J, Rio J, Alvarez Sabin J, Ortega A, Codina A. Posterior spinal artery infarction and nonbacterial thrombotic endocarditis. Neurologia 2002;17:117-20.

33. Ribó M, Montaner J, Molina C, Abilleira S, Arenillas J, Alvarez Sabin J. Chronic subdural hematoma simulating a TIA. Implications for the management of transient neurological deficit. Neurologia. 2002;17:342-4.

34. Arenillas JF, Rovira A, Molina CA, Grive E, Montaner J, Alvarez-Sabin J. Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke. 2002;33:2197-205.

35. Alvarez-Sabin J, Montaner J, Padro L, Molina C, Rovira R, Codina A, Quintana M. Gabapentin in late-onset poststroke seizures. Neurology. 2002;59:1991-3.

36. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J.


7

Matrix Metalloproteinase (MMP-9) pre-treatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.

37. Alvarez-Sabin J, Molina CA, Abilleira S, Montaner J, Garcia Alfranca F, Jimenez Fabrega X, Arenillas J, Huertas R, Ribo M, Quintana M, Codina A. Stroke code impact on the efficacy of thrombolytic treatment. Med Clin (Barc). 2003;120:47-51.

38. Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J. Thrombin-activable fibrinolysis inhibitor (TAFI) le vels in the acute phase of ischemic stroke. Stroke 2003;34:1038-1040.

39. Alvarez-Sabín J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribó M, Codina A, Quintana M. Serum glucose as a predictor of poor outcome in reperfused t-PA treated patients. Stroke 2003;34:1235-1241.

40. Abilleira S, Montaner J, Molina CA, Monasterio J, Castillo J, Alvarez-Sabín J. Matrix Metalloproteinase-9 (MMP-9) concentration after spontaneous intracerebral hemorrhage. Journal of Neurosurgery 2003;99:65-70.

41. Montaner J. Cooling matrix metalloproteinases to improve thrombolysis in acute ischemic stroke Stroke. 2003;34:2171-2172.

42. Montaner J, Alvarez-Sabín J, Codina A. Aportaciones radiológicas al síndrome de Opalski. Neurología. 2003;18:754.

43. Arenillas J, Alvarez-Sabín J, Molina CA, Chacón P, Montaner J, Rovira A, Ibarra B, Quintana M. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003;34:2463-2468.

44. Montaner J, Fernández-Cadenas I, Molina CA, Monasterio J, Arenillas JF, Ribó M, Quintana M, Chacón P, Andreu AL, Alvarez-Sabín J. Safety profile of t-PA treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the Matrix Metalloproteinase-9 gene. Stroke. 2003;34:2851-2855.

45. Montaner J, Rovira A, Molina CA, Arenillas JF, Ribó M, Chacón P, Monasterio J, Alvarez-Sabin J. Plasmatic level of neuroinflammatory markers (Matrix Metalloproteinase-9) predict the extent of Diffusion-Weighted Image lesion in hyperacute stroke. J Cereb Blood Flow Metab. 2003;23:1403-1407.

46. Ribó M, Montaner J, Monasterio J, Molina C, Arenillas J, Chacón P, Alvarez-Sabin J. Homocisteina en fase aguda del ictus. Neurologia. 2004;19:10-14.

47. Molina CA, Montaner J, Arenillas JF, Ribó M, Rubiera M, Alvarez-Sabín J.


8

Differential pattern of tissue Plasminogen Activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004;35:486-490.

48. Purroy Garcia F, Montaner J, Delgado P, Ribó M, Arenillas Lara JF, Quintana M, Alvarez-Sabín J.

Clinical factors predicting the appearance of vascular events following a transient ischemic attack. Rev Neurol. 2004;38:416-421. 49. Alvarez-Sabin J, Molina C, Montaner J, Arenillas J, Pujadas F, Huertas R, Mourino

J, Ribo M, Santamarina E, Quintana M. Clinical benefit following the implementation of a specialized urgent stroke care system. Med Clin (Barc). 2004;122:528-531. 50. Alvarez-Sabín J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M,

Santamarina E, Quintana M, Monasterio J, Montaner J. Temporal profile of Matrix Metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage. Relationship to clinical and radiological outcome. Stroke. 2004;35(6):1316-1322. 51. Arenillas JF, Molina CA, Chacón P, Rovira A, Montaner J, Sánchez E, Quintana M,

Penalba A, Alvarez-Sabín J. Serum lipoprotein (a) as an independent marker of the severity of intracranial large-vessel atherosclerosis. A case-control study. Neurology 2004;63(1):27-32.

52. Ribó M, Montaner J, Molina CA, Arenillas JF, Rubiera M, Alvarez-Sabín J. Baseline fibrinolytic profile predicts recanalization in tPA-treated patients. Thrombosis and Hemostasis 2004;91(6):1146-1151.

53. Ribó M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004;35:2123-2127.

54. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Chernyshev OY, Moyé LA, Hill MD, Wojner AW, for the CLOTBUST Investigators. A multi-center randomized trial of ultrasound-enhanced systemic

thrombolysis for acute ischemic stroke. NEJM. 2004;351:2170-2178. 55. Purroy F, Montaner J, Rovira A, Delgado P, Quintana M, Alvarez-Sabin J.

Higher risk of further vascular events among transient ischemic attack patients with Diffusion-Weighted Imaging acute ischemic lesions. Stroke. 2004; 35:2313-2319.

56. Alvarez-Sabin J, Molina CA, Ribo M, Arenillas JF, Montaner J, Huertas R, Santamarina E, Rubiera M.

Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke. 2004;35:2493-2498. 57. Monasterio J, Bermudez P, Quiroga D, Francisco E, Meneses B, Montaner J. Plasma Thrombin-Activatable Fibrinolytic Inhibitor (TAFI) among healthy


9

subjects and patients with vascular diseases: A validation study. Pathophysiol Haemost Thromb. 2004;33(5-6):382-386. 58. Arenillas JF, Álvarez-Sabín J, Montaner J, Rosell A, Molina CA, Rovira A, Ribó M,

Sánchez E, Quintana M. Angiogenesis in symptomatic intracranial atherosclerosis: Predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 2005;36:92-97.

59. Boulanger JM, Coutts SB, Hill MD, Demchuk AM, Buchan AM, For the Calgary Stroke Program, Purroy F, Montaner J, Delgado P, Alvarez-Sabin J. Use of magnetic resonance imaging in predicting further vascular events among patients with transient ischemic attacks * Response. Stroke 2005; 36:526-528.

60. Ribó M, Molina CA, Rovira A, Quintana M, Delgado P, Montaner J, Grive E, Arenillas JF, Álvarez-Sabín J. Safety and efficacy of intravenous tissue Plasminogen Activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005;36:602-606.

61. Arenillas JF, Candell-Riera J, Romero-Farina G, Molina CA, Chacón P, Aguadé-Bruix S, Montaner J, de León G, Castell-Conesa J, Alvarez-Sabín J. Silent myocardial ischemia in patients with symptomatic intracranial atherosclerosis: Associated factors. Stroke 2005;36:1201-6.

62. Delgado P, Montaner J, Chacón P, Purroy F, Ribo M, Alvarez-Sabín J. Lipid profile in the hyperacute phase of ischemic stroke allows to decide cholesterol-lowering therapy. Med Clin (Barc) 2005;124:295-7.

63. Valable S, Montaner J, Bellail A, Berezowski V, Brillaut J, Cecchelli R, Divoux D, MacKenzie ET, Bernaudin M, Roussel S, Petit E. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1 J Cereb Blood Flow Metab. 2005;25(11):1491-504.

64. Rubiera M, Álvarez-Sabín J, Ribó M, Montaner J, Santamarina E, Arenillas JF, Huertas R, Delgado R, Purroy F, Molina CA. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005;36:1452-1456.

65. Rosell A, Alvarez-Sabín J, Arenillas JF, Rovira A, Delgado P, Fernández-Cadenas I, Penalba A, Molina C, Montaner J. A Matrix Metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with Diffusion-Weighted Image lesion increase in human stroke Stroke 2005;36:1415-1420.

66. Martí-Fàbregas J, Borrell M, Cocho D, Belvís R, Castellanos M, Montaner J, Pagonabarraga J, Aleu A, Molina-Porcel L, Díaz-Manera J, Bravo Y, Álvarez-Sabín J, Dávalos A, Fontcuberta J, Martí-Vilalta JL. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 2005;65:366-370.


10

67. Ribo M, Molina C, Montaner J, Rubiera M, Delgado-Mederos R, Arenillas JF, Quintana M, Alvarez-Sabín J. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients Stroke 2005;36:1705-1709.

68. Tsuji K, Aoki T, Tejima E, Arai K, Lee S, Huang PL, Wang X, Montaner J, Lo EH. Tissue Plasminogen Activator promotes Matrix Metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005;36:1954-1959.

69. Miguel M, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, Alvarez-Sabin J, Cairols M, Badimon L. Matrix metalloproteinases in atherosclerotic plaque and plasma of patients with advanced carotid atherosclerosis. Atherosclerosis 2006;187(1):161-169.

70. Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, Arenillas JF, Huertas R, Purroy F, Delgado P, Alvarez-Sabin J. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke. 2006;37(2):425-429.

71. Fernández-Cadenas I, Molina CA, Alvarez-Sabín J, Ribó M, Penalba A, Ortega-Torres L, Delgado P, Quintana M, Rosell A, Montaner J. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters 2006;398(3):167-71.

72. Fernández-Cadenas I, Alvarez-Sabín J, Molina CA, Ribó M, Penalba A, Ortega-Torres L, Delgado P, Rosell A, Montaner J. Influencia del genotipo del ApoE sobre la eficacia y seguridad del tratamiento trombolítico en el ictus isquémico. Neurologia 2006;21(4):176-180.

73. Cocho D, Borrell M, Marti-Fabregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvis R, Diaz-Manera JA, Martinez-Domeno A, Martinez-Lage M, Millan M, Fontcuberta J, Marti-Vilalta JL. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue Plasminogen Activator. Stroke 2006;37(4):996-9.

74. Ribo M, Alvarez-Sabin J, Montaner J, Romero F, Delgado P, Rubiera M, Delgado-Mederos R, Molina CA. Temporal profile of recanalization after intravenous tissue Plasminogen Activator. Selecting patients for rescue reperfusion techniques. Stroke 2006;37(4):1000-4.

75. Montaner J, Fernandez-Cadenas I, Molina CA, Ribo M, Huertas R, Rosell A, Penalba A, Ortega L, Chacon P, Alvarez-Sabin J. Post-stroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006; 37(5):1205-10.

76. González-Conejero R, Fernández-Cadenas I, Iniesta JA, Marti-Fabregas J, Obach V, Alvarez-Sabín J, Vicente V, Corral J, Montaner J.


11

Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006;37(9):2288-2293.

77. Montaner J, Alvarez-Sabín J. La escala de ictus de la NIH y su adaptación al español Neurología 2006;21(4):192-202.

78. Delgado P, Alvarez-Sabín J, Abilleira S, Santamarina E, Purroy F, Arenillas JF, Molina CA, Fernández-Cadenas I, Rosell A, Montaner J.

Plasma D-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology 2006; 67: 94-98. 79. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina

CA, Lo EH, Montaner J. Increased brain expression of Matrix Metalloproteinase-9 following ischemic and hemorrhagic human stroke.

Stroke 2006;37(6):1399-1406. 80. Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, Lo EH. Reduction of tissue Plasminogen Activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes.

Stroke 2006;37(7):1910-1912. 81. Delgado-Mederos R, Ribo M, Montaner J, Arenillas JF, Rubiera M, Alvarez-Sabin

J, Molina CA. Real-time monitoring of recanalization after intravenous thrombolysis for acute ischemic stroke. Eur J Neurol. 2006;13:426-427. 82. Purroy F, Montaner J, Delgado P, Arenillas JF, Molina CA, Santamarina E,

Quintana M, Alvarez-Sabin J. Usefulness of urgent combined carotid/transcranial ultrasound testing in early prognosis of TIA patients. Med Clin (Barc). 2006;126:647-650. 83. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Delgado P, Montaner J,

Alvarez-Sabin J, Molina CA. Tandem internal carotid artery/middle cerebral artery occlusion. An independent predictor of poor outcome after systemic thrombolysis. Stroke. 2006;37(9):2301-2305. 84. Delgado P, Álvarez Sabin J, Santamarina E, Molina CA, Quintana M, Rosell A,

Montaner J. Blood S100B level after acute spontaneous intracerebral hemorrhage. Stroke. 2006;37(11):2837-9. 85. Roquer J, Rodriguez-Campello A, Gomis M, Ois A, Martinez-Rodriguez JE, Munteis E, Jimenez Conde J, Montaner J, Alvarez Sabin J. Comparison of the impact of atrial fibrillation on the risk of early death after stroke in women versus men. J Neurol. 2006;253(11):1484-9. 86. Montaner J. Response to Letter by Topakian et al. (Admission C-Reactive Protein as a predictor for stroke outcome among candidates for thrombolysis: Decision adjourned.) Stroke. 2006 Aug 24; [Epub ahead of print]


12

87. Mendioroz M, Fernandez-Cadenas I, Montaner J. Neurological manifestations of Fabry disease. Rev Neurol. 2006;43(12):739-45. 88. Tejima E, Zhao BQ, Tsuji K, Rossell A, Leyen K, Gonzalez RG, Montaner J, Wang

X, Lo EH. Astrocytic induction of Matrix Metalloproteinase-9 and edema in brain hemorrhage.

J Cereb Blood Flow Metab. 2007;27:460-468. 89. Purroy F, Montaner J, Molina CA, Delgado P, Arenillas JF, Chacon P, Quintana M,

Alvarez-Sabin J. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand. 2007;115(1):60-66. 90. Purroy F, Molina CA, Montaner J, Álvarez-Sabín J. Absence of Usefulness of ABCD Score in the Early Risk of Stroke of Transient Ischemic Attack Patients. Stroke. 2007;38:855-856. 91. Delgado-Mederos R, Rovira A, Alvarez-Sabin J, Ribo M, Munuera J, Rubiera M, Santamarina E, Maisterra O, Delgado P, Montaner J, Molina CA. Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke. 2007;38:955-960. 92. Allard L, Turck N, Burkhard PR, Walter N, Rosell A, Gex-Fabry M, Hochstrasser

DF, Montaner J, Sanchez JC. Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke. Biomark Insights. 2007 Apr 19;2:155-64. 93. Alvarez-Sabín J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, Molina

CA, Montaner J. Prior statin use may be associated with improved outcome after rt-PA. Stroke. 2007;38:1076-1078. 94. Foerch C, Wunderlich MT, Yan B, Dvorak F, Humpich M, Kahles T, Goertler M,

Alvarez-Sabín J, Wallesch CW, Molina CA, Sitzer M, Montaner J. Elevated serum S100B levels indicate a higher risk of haemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 2007;38:2491-2495. 95. Navarro-Núñez L, Lozano ML, Rivera J, Corral J, Roldán V, González-Conejero R,

Iniesta JA, Montaner J, Vicente V, Martínez C. The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica 2007;92(4):513-518. 96. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina

CA, Rosell A, Montaner J. Fibrinolysis inhibitor genes (TAFI/PAI-1) influence t-PA-induced recanalization among ischemic stroke patients. Journal of Thrombosis and Haemostasis 2007;5:1862-1868. 97. Purroy F, Montaner J, Molina CA, Delgado P, Ribo M, Álvarez-Sabín J. Patterns and predictors of early risk of recurrence following transient ischemic attack regarding etiological subtypes.


13

Stroke. 2007;38(12):3225-3229. 98. Fernandez-Cadenas I, Nogales-Gadea G, Llige D, Rubio JC, Montaner J, Arenas J,

Raspall-Chaure M, Roig-Quilis M, Andreu AL. Private mutations in the myophosphorylase gene: the first case in a patient of Latin American descent. Rev Neurol. 2007;45:280-283. 99. Slevin M, Krupinski J, Mitsios N, Perikleous C, Cuadrado E, Montaner J, Sanfeliu C, Luque A, Kumar S, Kumar P, Gaffney J. Leukaemia inhibitory factor is over-expressed by ischaemic brain tissue concomitant with reduced plasma expression following acute stroke. Eur J Neurol. 2008;15(1):29-37. 100. Montaner J, Chacón P, Krupinski J, Rubio F, Millán M, Molina CA, Hereu P,

Quintana M, Alvarez-Sabín J. Simvastatin in the Acute Phase of Ischemic Stroke: A Safety and Efficacy Pilot Trial. Eur J Neurol 2008;15(1):82-90. 101. Montaner J. Cholesterol measured before stroke thrombolysis is not associated with t-PA- related hemorrhagic transformation. Stroke. 2008 Jan;39(1):e6. Epub 2007 Nov 29. 102. Rosell A, Cuadrado E, Alvarez-Sabín J, Hernandez-Guillamon M, Delgado P,

Penalba A, Mendioroz M, Rovira A, Fernández-Cadenas I, Ribó M, Molina CA, Montaner J.

Caspase-3 Is Related to Infarct Growth after Human Ischemic Stroke. Neuroscience Letters 2008;430(1):1-6.

103. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J.

MMP-9-positive neutrophil infiltration is associated to BBB breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008;39(4):1121-6. 104. Saqqur M, Tsivgoulis G, Molina C, Demchuk A, Garami Z, Barreto A, Spengos

K, Forteza A, Mikulik R, Sharma V, Brusner A, Martinez P, Montaner J, Kohrmann M, Schellinger P, Alexandrov A.

Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO). International Journal of Stroke 2008;3(1):66-72. 105. Arenillas JF, Álvarez-Sabín J, Molina C, Chacón P, Fernández-Cadenas I, Ribó

M, Delgado P, Rubiera M, Penalba A, Rovira A, Montaner J. Progression of symptomatic intracranial large-artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke. 2008;39:1456-1463. 106. Delgado P, Cuadrado E, Rosell A, Alvarez-Sabin J, Ortega-Aznar A, Hernández

M, Penalba A, Molina CA, Montaner J. Fas system activation in perihematomal areas after spontaneous intracerebral Hemorrhage. Stroke. 2008;39:1730-1734. 107. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, Quintana

M, Palacios ME, Molina CA, Alvarez-Sabín J.


14

Etiologic Diagnosis of Ischemic Stroke Subtypes Using Plasma Biomarkers. Stroke. 2008;39:2280-2287. 108. Cuadrado E, Ortega L, Hernández-Guillamon M, Penalba A, Fernández-Cadenas

I, Rosell A, Montaner J. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. Journal of Leukocyte Biology. 2008;84(1):207-14. 109. Vilalta A, Sahuquillo J, Rosell A, Poca M.A., Riveiro M, Montaner J. Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med. 2008;34(8):1384-92. 110. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Maisterra O, Delgado

P, Montaner J, Alvarez-Sabín J, Molina CA. Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated With Microbubble-Enhanced Sonothrombolysis? Ultrasound Med Biol. 2008;34(10):1573-7. 111. Cuadrado E, Rosell Novel A, Borrell-Pagès M, García-Bonilla L, Hernández-

Guillamon M, Ortega A, Montaner J. Matrix Metalloproteinase-13 is activated and is found in the nucleus of neural cells following cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 2009;29(2):398-410 112. Castillo J, Álvarez-Sabín J, Martínez-Vila E, Montaner J, Sobrino T, Vivancos J,

on behalf of the MÍTICO Study Investigators. Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study. Journal of Neurology 2009;256(2):217-224. 113. Hernandez-Guillamon M, Delgado P, Ortega L, Pares M, Rosell A, Fernandez-

Cadenas I, Garcia-Bonilla L, Borrell-Pages M, Boada M, Montaner J. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by ß-amyloid 25-35 fragment. Journal of Neuroscience Research 2009;87(9):2115-25. 114. Rosell A, Arai K, Lok J, He T, Guo S, Navarro M, Montaner J, Katusic Z, Lo E. Interleukin-1β Augments Angiogenic Responses of Murine Endothelial Progenitor Cells in vitro. Journal of Cerebral Blood Flow and Metabolism 2009;29(5):933-43. 115. Mendioroz M, Fernandez-Cadenas I, Alvarez-Sabín J, Rosell A, Quiroga D,

Cuadrado-Godia E, Delgado P, Rubiera M, Ribo M, Molina C, Montaner J. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tPA treatment in stroke patients. Cerebrovascular Diseases 2009;28:143-150. 116. Arenillas JF, Massot A, Fernandez-Cadenas I, del Rio A, Chacón P, Quintana M,

Molina CA, Álvarez-Sabín J, Rovira A, Montaner J. C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovascular Diseases 2009;28(1):95-102. 117. Cuadrado E, Rosell A, Penalba A, Slevin M, Alvarez-Sabin J, Ortega-Aznar A,

Montaner J. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined Laser Microdissection and Protein Array


15

Study. Journal of Proteome Research 2009;8(6):3191-3197. 118. Roussel BD, Macrez R, Agin V, Castel H, Maubert E, Dauphinot L, Potier MC,

Plawinski L, Jullienne A, Hommet Y, Munuera J, Montaner J, Yepes M, Ali C, Vivien D.

Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact Brain 2009;132(Pt 8):2219-30. 119. Mendióroz M, Jericó-Pascual I, Méndez I, Gastón-Zubimendi I, Arteaga J, Montaner J. Hyperintensity in the anterior region of the temporal lobes in Fabry's disease. Rev Neurol. 2009;48(11):599-600. 120. Alvarez-Sabín J, Penalba A, Quintana M, Krupinski J, García-Bonilla L,

Montaner J. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. Cerebrovascular Diseases 2009;28(4):371-377. 121. Fernandez-Cadenas I, Mendioroz M, Munuera J, Alvarez-Sabin J, Rovira A,

Quiroga A, Corbeto N, Rubiera M, Delgado P, Rosell A, Ribó M, Molina CA, Montaner J.

Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thromb Haemost. 2009;102(4):759-64. 122. Navarro M, Rosell A, Penalba A, Ribó M, Alvarez-Sabín J, Fernández-Cadenas

I, Montaner J. Role of endogenous Granulocyte-Macrophage Colony Stimulating Factor following stroke and relationship to neurological outcome. Current Neurovascular Research 2009;6(4):246-51. 123. Domingues-Montanari S, Fernández-Cadenas I, del Río-Espinola A, Mendioroz

M, Fernandez-Morales J, Corbeto N, Delgado P, Ribó M, Rubiera M, Obach V, Martí-Fàbregas J, Freijo M, Serena J, Montaner J.

KCNK17 genetic variants in ischemic stroke. Atherosclerosis 2010;208(1):203-209. 124. Blanco M, Sobrino T, Montaner J, Medrano V, Jiménez C, Masjuán J, Gómez-

Escalonilla C, de Luis P, Arboix A, Castillo J, on behalf of the MÍTICO Study. Stroke with polyvascular atherothrombotic disease. Atherosclerosis 2010;208(2):587-92. 125. Yang Y, Candelario-Jalil E, Thompson JF, Cuadrado E, Estrada EY, Rosell A,

Montaner J, Rosenberg GA. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. Journal of Neurochem 2010;112(1):134-49. 126. Domínguez C, Delgado P, Vilches A, Martín-Gallán P, Ribó M, Santamarina E,

Molina C, Corbeto N, Rodríguez-Sureda V, Rosell A, Alvarez-Sabín J, Montaner J. Oxidative stress following thrombolysis-induced reperfusion in human stroke. Stroke 2010;41(4):653-60. 127. Fernandez-Cadenas I, Del Rio-Espinola A, Rubiera M, Mendioroz M,

Domingues-Montanari S, Cuadrado E, Hernandez-Guillamon M, Rosell A, Ribo M, Alvarez-Sabin J, Molina CA, Montaner J.


16

PAI-1 4G5G polymorphism is associated with brain vessel reocclusion after successful fibrinolytic therapy in ischemic stroke patients. Int J Neurosci 2010;120(4):245-51. 128. Domingues-Montanari S, Fernández-Cadenas I, del Rio-Espinola A, Krug T,

Manso H, Gouveia L, Sobral J, Mendioroz M, Fernandez-Morales J, Ribó M, Rubiera M, Obach V, Martí-Fàbregas J, Freijo M, Serena J, Ferro JM, Vicente AM, Oliveira SA, Montaner J.

Association of a genetic variant in the ALOX5AP gene with higher risk of ischemic stroke. A case-control, meta-analysis and functional study. Cerebrovascular Diseases 2010;29(6):528-537. 129. Palenzuela L, Mas A, Montaner J, Cordoba J. Matrix metalloproteinase-9 in fulminant hepatic failure. Hepatology. 2010;51(4):1475-1476. 130. Domingues-Montanari S, Hernandez-Guillamon M, Fernandez-Cadenas I,

Mendioroz M, Boada M, Munuera J, Rovira A, Maisterra O, Parés M, Gutierrez M, Alvarez-Sabin J, Chacón P, Delgado P, Montaner J.

ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging 2010;32(3):551.e13-22. 131. del Río-Espínola A, Fernández-Cadenas I, Rubiera M, Quintana M, Domingues-

Montanari S, Mendióroz M, Fernández-Morales J, Giralt D, Molina CA, Alvarez-Sabín JA, Montaner J.

CD40 -1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics 2010;11(6):763-72. 132. Domingues-Montanari S, Fernandez-Cadenas I, Del Rio-Espinola A, Mendioroz

M, Ribo M, Obach V, Martí-Fàbregas J, Freijo M, Serena Leal J, Chacón P, Alvarez-Sabin J, Montaner J.

The I/D polymorphism of the ACE1 gene is not associated with ischemic stroke in Spanish individuals. European Journal of Neurology 2010;17(11):1390-2. 133. Hernández-Guillamon M, Garcia-Bonilla L, Solé M, Sosti V, Parés M, Campos

M, Ortega-Aznar A, Domínguez C, Rubiera M, Ribó M, Quintana M, Molina CA, Alvarez-Sabín J, Rosell A, Unzeta M, Montaner J.

Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tPA treatment in stroke. Stroke 2010;41(7):1528-35. 134. Hernandez-Guillamon M, Mawhirt S, Fossati S, Blais S, Pares M, Penalba A,

Boada M, Couraud PO, Neubert T, Montaner J, Ghiso J, Rostagno A. MMP-2 degrades soluble vasculotropic amyloid-ß E22Q and L34V mutants delaying their toxicity for human brain microvascular endothelial cells. Journal of Biological Chemistry 2010;285(35):27144-58. 135. Arsava EM, Ballabio E, Cole J, Delgado-Martinez MP, Dichgans M, Fazekas F,

Furie KL, Illoh K, Jood K, Kittner S, Koroshetz WJ, Lindgren AG, Majersik J, Meurer WJ, Montaner J, Norrving B, Olugbodi AA, Pasdar A, Redfors P, Schmidt R, Sharma P, Singhal A, Sorensen AG, Sudlow C, Thijs V, Worrall B, Rosand J, Ay H, on behalf of the International Stroke Genetics Consortium.

The Causative Classification of Stroke System. An International Reliability and Optimization Study.


17

Neurology 2010;75(14):1277-1284. 136. Lemmens R, Buysschaert I, Geelen V, Fernandez I, Montaner J, Schmidt H,

Schmidt R, Attia J, Levi C, Jood K, Jern C, Wnuk M, Slowik A, Lambrechts D, Thijs V; International Stroke Genetics Consortium

The association of the 4q25 susceptibility variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke 2010;41(9):1850-7. 137. Mendioroz M, Fernandez-Cadenas I, del Río-Espínola A, Rovira A, Sole E,

Fernández-Figueras MT, García-Patos V, Sastre-Garriga J, Domingues-Montanari S, Alvarez-Sabin J, Montaner J.

A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population. Neurology 2010;75(22):2033-5. 138. Biffi A, Sonni A, Anderson CD, Jagiella JM, Schmidt H, Jimenez-Conde J,

Fernandez I, Cortellini L, Ayres A, Schwab K, Juchniewicz K, Urbanik A, Rost NS, Viswanathan A, Seifert T, Montaner J, Kidwell CS, Brown DS, Silliman SL, Selim M, Worrall BB, Meschia JF, Roquer J, Schmidt R, Greenberg SM, Slowik A, Broderick JP, Woo D, Rosand J, on behalf of the ISGC.

Variants at APOE Influence Risk of Deep and Lobar Intracerebral Hemorrhage Annals of Neurology 2010;68(6):934-43. 139. Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Ribó M,

Alvarez-Sabín J, Montaner J. Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvasc Res. 2010;80(3):317-23. 140. Montaner J, Salat D, García-Berrocoso T, Molina CA, Chacón P, Ribó M,

Alvarez-Sabín J, Rosell A. Reperfusion therapy for acute stroke improves outcome by decreasing neuroinflammation. Translational Stroke Research 2010;1:261-267. 141. Cuadrado E, Rosell A, Colomé N, Hernández-Guillamon M, García-Berrocoso

T, Ribó M, Alcazar A, Ortega-Aznar A, Salinas M, Canals F, Montaner J. The proteome of human brain after ischemic stroke. J Neuropath Exp Neurol 2010;69(11):1105-15. 142. Fernández-Cadenas I, Mendioroz M, Domingues-Montanari S, Del Rio-Espinola

A, Delgado P, Ruiz A, Hernandez-Guillamon M, Giralt D, Chacon P, Navarro-Sobrino M, Ribo M, Molina CA, Alvarez-Sabin J, Rosell A, Montaner J.

Leukoaraiosis is associated with genes regulating blood brain barrier homeostasis in ischemic stroke patients. European Journal of Neurology 2011;18(6):826-35. 143. Mendioroz M, Fernández-Cadenas I, Rosell A, Delgado P, Domingues-

Montanari S, Ribó M, Penalba A, Quintana M, Alvarez-Sabín J, Montaner J. Osteopontin predicts long-term functional outcome among ischemic stroke patients Journal of Neurology 2011;258(3):486-93. 144. Montaner J, Mendioroz M, Ribo M, Delgado P, Quintana M, Penalba A, Chacon

P, Molina C, Fernandez-Cadenas I, Rosell A, Álvarez-Sabín J. A panel of biomarkers including caspase-3 and D-dimer may differentiate acute


18

stroke from stroke mimicking conditions at the Emergency Department. Journal of Internal Medicine 2011;270(2):166-74. 145. del Río-Espínola A, Fernández-Cadenas I, Mendióroz M, Gutiérrez-Agullo M,

Fernández MT, Fernández-Morales J, Delgado P, Domingues-Montanari S, Solé E, Montaner J. Novel human pathological mutations. Gene symbol: NOTCH3. Disease: CADASIL. Hum Genet. 2010;127(4):473-4

146. del Río-Espínola A, Fernández-Cadenas I, Mendióroz M, Gutiérrez-Agulló M, Fernández MT, Fernández-Morales J, Maisterra O, Domingues-Montanari S, García-Patos V, Solé E, Montaner J. Novel human pathological mutations. Gene symbol: NOTCH3. Disease: CADASIL. Hum Genet. 2010;127(4):474.

147. Salat D, Delgado P, Alonso S, Ribó M, Santamarina E, Quintana M, Alvarez-Sabín J, Montaner J.

Early infection and ischemic stroke outcome: its deleterious effect seems to operate also among tPA-treated patients. European Journal of Neurology 2011;65(2):82-87. 148. Rosell A, Vilalta A, García-Berrocoso T, Fernández-Cadenas I, Cuadrado E,

Delgado P, Ribó M, Martínez-Díaz E, Ortega-Aznar A, Montaner J. Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage PLoS ONE 2011;6(2):e16750. 149. Garcia-Bonilla L, Sosti V, Campos M, Penalba A, Sumalla M, Hernández-

Guillamon M, Rosell A, Montaner J. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Research 2011;1373:211-20. 150. Dayon L, Turck N, Garcia-Berrocoso T, Walter N, Burkhard PR, Vilalta A,

Sahuquillo J, Montaner J, Sanchez JC. Brain extracellular fluid protein changes in acute stroke patients. Journal of Proteome Research. 2011;10(3):1043-1051. Epub 2011 Jan 18. 151. Navarro-Sobrino M, Rosell A, Hernández-Guillamon M, Penalba A, Boada C,

Domingues-Montanari S, Ribó M, Alvarez-Sabín J, Montaner J. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis. 2011;216(1):205-11.

152. Macrez R, Obiang P, Gauberti M, Roussel BD, Baron AF, Parcq J, Cassé F, Orset C, Hommet Y, Agin V, Bezin L, Garcia Berrocoso T, Petersen KU, Montaner J, Maubert E, Vivien D, Ali C. Antibody therapy preventing the interaction of tPA with NMDA receptors reduces ischemic stroke damages and extends the therapeutic window of thrombolysis

Stroke. 2011;42(8):2315-22. 153. Domingues-Montanari S, Parés M, Hernández-Guillamon M, Fernández-

Cadenas I, Mendioroz M, Ortega G, Boada M, Masjuan J, Huertas N, Alvarez-Sabín J, Delgado P, Montaner J; for the Stroke Project of the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.


19

No evidence of APP point mutation and locus duplication in individuals with cerebral amyloid angiopathy. European Journal of Neurology. 2011 ;18(10):1279-81.

154. Massot A, Pelegri D, Penalba A, Arenillas J, Boada C, Giralt D, Ribó M, Molina CA, Rosell A, Alvarez-Sabín J, Chacón P, Rovira A, Delgado P, Montaner J. Lipoprotein-Associated Phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis 2011;218(1):181-7.

155. Rodríguez-Luna D, Rubiera M, Ribó M, Coscojuela P, Piñeiro S, Pagola J, Hernández-Guillamon M, Ibarra B, Romero F, Álvarez-Sabín J, Montaner J, Molina CA. Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage.

Neurology. 2011;77(17):1599-604. 156. Steiner T, Petersson J, Al-Shahi Salman R, Cordonnier C, Csiba L, Harnof S,

Krieger D, Mendelow D, Molina C, Montaner J, Overgaard K, Roine R, Schmutzhard E, Tatlisumak T, Toni D, Stapf C, for the European Research Network on Intracerebral Haemorrhage (EURONICH).

European Research Priorities for Intracerebral Haemorrhage Cerebrovascular Diseases 2011;32(5):409-419.

157. Montaner J. Genetics of intracerebral haemorrhage: a tsunami effect of APOE ɛ2 genotype on brain bleeding size? Lancet Neurol. 2011;10(8):673-5

158. Hernandez-Guillamon, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovascular Diseases 2011;33(1):55-63.

159. Giralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Gainza M, Delgado P, Rosell A, Montaner J.

The gender gap in stroke: a meta-analysis. Acta Neurologica Scand. 2012;125(2):83-90. 160. Barral S, Fernández-Cadenas I, Bis JC, Montaner J, Ikram AM, Launer LJ,

Fornage M, Schmidt H, Brickman AM, Seshadri S, Mayeux R. No association of ALOX5AP polymorphisms with risk of MRI-defined brain infarcts. Neurobiology of Aging 2012;33(3):629.e1-3.

161. Hernández-Guillamon M, Martinez-Saez E, Delgado P, Domingues-Montanari S, Boada C, Penalba A, Boada M, Pagola J, Maisterra O, Rodriguez-Luna D, Molina CA, Rovira A, Alvarez-Sabin J, Ortega-Aznar A, Montaner J. MMP-2/MMP-9 plasma level and brain expression in Cerebral Amyloid Angiopathy-associated hemorrhagic stroke. Brain Pathology 2012;22(2):133-41.

162. Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, Alvarez-Sabin J, Boada M, Montaner J. Plasma β-amyloid levels in Cerebral Amyloid Angiopathy-associated hemorrhagic Stroke.

Neurodegenerative Diseases 2012;10(1-4):320-3.


20

163. Delgado P, Chacón P, Penalba A, Pelegri D, García-Berrocoso T, Giralt D, Santamarina E, Ribó M, Maisterra O, Alvarez-Sabín J, Rosell A, Montaner J. Lipoprotein-associated phospholipase A2 activity is associated with large artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovascular Diseases 2012;33(2):150-158

164. Delgado P, Chacón P, Penalba A, Pelegrí D, Merino C, Ribó M, Rubiera M, Álvarez-Sabin J, Montaner J. Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis 2012;220(2):532-6.

165. Fernández-Cadenas I, del Río-Espínola A, Carrera C, Domingues-Montanari S, Mendióroz M, Delgado P, Rosell A, Ribó M, Giralt D, Quintana M, Castellanos M, Obach V, Martínez S, Freijo MM, Jiménez-Conde J, Roquer J, Martí-Fábregas J, Molina CA, Álvarez-Sabín J, Montaner J. Role of the MMP9 gene in hemorrhagic transformations after t-PA treatment in stroke patients. Stroke 2012 May;43(5):1398-400.

166. Mendonça N, Rodriguez-Luna D, Rubiera M, Boned-Riera S, Ribo M, Pagola J, Piñeiro S, Meler P, Alvarez-Sabin J, Montaner J, Molina CA. Predictors of Tissue-Type Plasminogen Activator Nonresponders According to Location of Vessel Occlusion. Stroke. 2012;43:417-21.

167. Vidaurre OG, Gascón S, Deogracias R, Sobrado M, Cuadrado E, Montaner J, Rodríguez-Peña A, Díaz-Guerra M. Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death & Disease. 2012 Jan 19;3:e256.

168. Krug T, Gabriel JP, Taipa R, Fonseca BV, Domingues-Montanari S, Fernandez-Cadenas I, Manso H, Gouveia LO, Sobral J, Albergaria I, Gaspar G, Jiménez-Conde J, Rabionet R, Ferro JM, Montaner J, Vicente AM, Silva MR, Matos I, Lopes G, Oliveira SA. TTC7B emerges as a novel risk factor for ischemic stroke through the convergence of several genome-wide approaches. J Cereb Blood Flow Metab. 2012;32(6):1061-72.

169. Flores A, Sargento-Freitas J, Pagola J, Rodriguez-Luna D, Piñeiro S, Maisterra O, Rubiera M, Montaner J, Alvarez-Sabin J, Molina C, Ribo M. Arterial Blood Gas Analysis of Samples Directly Obtained Beyond Cerebral Arterial Occlusion During Endovascular Procedures Predicts Clinical Outcome. J Neuroimaging. 2011 Dec 30. doi: 10.1111/j.1552-6569.2011.00667.x. [Epub ahead of print]

170. Morancho A, García-Bonilla L, Barceló V, Giralt D, Campos-Martorell M, Garcia S, Montaner J, Rosell A. A New Method For Focal Transient Cerebral Ischemia By Distal Compression Of The Middle Cerebral Artery. Neuropathol Appl Neurobiol. 2012 Oct;38(6):617-27.

171. Montaner J, Mendioroz M, Delgado P, García-Berrocoso T, Giralt D, Merino C, Ribó M, Rosell A, Penalba A, Fernández-Cadenas I, Romero F, Molina C, Alvarez-Sabín J, Hernández-Guillamon M.


21

Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. J Proteomics. 2012;75(15):4758-65.

172. Santamarina E, Penalba A, García-Berrocoso T, Delgado P, Quintana M, González-Alujas T, Ribó M, Maisterra O, Molina CA, Evangelista A, Álvarez-Sabín J , Montaner J. Biomarkers Level Improve the Diagnosis of Embolic Source in Ischemic Stroke of Unknown Origin. J Neurol. 2012;259(12):2538-45.

173. García-Bonilla L, Campos M, Giralt D, Salat D, Chacón P, Hernández-Guillamon M, Rosell M, Montaner J. Evidence for the efficacy of statins in animal stroke models: a meta-analysis. Journal of Neurochemistry 2012 Apr 30. doi: 10.1111/j.1471-4159.2012.07773.x.

174. Moniche F, Gonzalez A, Gonzalez-Marcos JR, Carmona M, Piñero P, Espigado I, Garcia-Solis D, Cayuela A, Montaner J, Boada C, Rosell A, Jimenez MD, Mayol A, Gil-Peralta A. Intra-Arterial Bone Marrow Mononuclear Cells in Isc hemic Stroke: A Pilot Clinical Trial. Stroke. 2012;43(8):2242-4.

175. Del Río-Espínola A, Fernández-Cadenas I, Giralt D, Quiroga A, Gutiérrez-Agulló M, Quintana M, Fernández-Álvarez P, Domingues-Montanari S, Mendióroz M, Delgado P, Turck N, Ruíz A, Ribó M, Castellanos M, Obach V, Martínez S, Freijo MM, Jiménez-Conde J, Cuadrado-Godia E, Roquer J, Chacón P, Martí-Fábregas J, Sánchez JC; the GRECOS Investigators, Montaner J. A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke. Ann Neurol. 2012;72(5):716-729.

176. Fernández-Cadenas I, Del Río-Espínola A, Giralt D, Domingues-Montanari S, Quiroga A, Mendióroz M, Ruíz A, Ribó M, Serena J, Obach V, Freijo MM, Martí-Fábregas J, Delgado P, Montaner J. IL1B and VWF variants are associated with fibrinolytic treatment efficacy in ischemic stroke patients Stroke. 2012;43(10):2659-65.

177. Falcone GJ, Biffi A, Devan WJ, Jagiella JM, Schmidt H, Kissela B, Hansen BM, Jimenez-Conde J, Giralt-Steinhauer E, Elosua R, Cuadrado-Godia E, Soriano C, Ayres AM, Schwab K, Pera J, Urbanik A, Rost NS, Goldstein JN, Viswanathan A, Pichler A, Enzinger C, Norrving B, Tirschwell DL, Selim M, Brown DL, Silliman SL, Worrall BB, Meschia JF, Kidwell CS, Montaner J, Fernandez-Cadenas I, Delgado P, Broderick JP, Greenberg SM, Roquer J, Lindgren A, Slowik A, Schmidt R, Flaherty ML, Kleindorfer DO, Langefeld CD, Woo D, Rosand J; on behalf of the Internacional Stroke Genetics Consortium. Burden of Risk Alleles for Hypertension Increases Risk of Intracerebral Hemorrhage. Burden of risk alleles for Hypertension Increases Risk of Intracerebral Hemorrhage Stroke. 2012;43(11):2877-83.

178. Riba I, Jarca CI, Mundet X, Tovar JL, Orfila F, Nafría C, Raga A, Girona A, Fernández-Lara P, Castañé X, Álvarez Sabin J, Fernández Cortiñas I, Maisterra O, Montaner J, Delgado P. Cognitive assessment protocol design in the ISSYS study (Investigating Silent


22

Strokes in hYpertensives: a magnetic resonance imaging Study). J Neurol Sci. 2012;322(1-2):79-81.

179. Montaner J, García-Berrocoso T, Mendioroz M, Palacios M, Perea-Gainza M, Delgado P, Rosell A, Slevin M, Ribó M, Molina CA, Alvarez-Sabín J. Brain Natriuretic Peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. Cerebrovascular Diseases 2012;34(3):240-245.

180. Turck N, Robin X, Walter N, Fouda C, Hainard A, Sztajzel R, Wagner G, Hochstrasser DF, Montaner J, Burkhard PR, Sanchez JC. Blood Glutathione S-Transferase-π as a Time Indicator of Stroke Onset. PLoS One. 2012;7(9):e43830. Epub 2012 Sep 17. PubMed PMID: 23028472.

181. Bustamante A, Giralt D, Garcia-Bonilla L, Campos M, Rosell A, Montaner J. Citicoline in pre-clinical animal models of stroke: A meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem. 2012;123(2):217-25.

182. Yigitkanli K, Pekcec A, Karatas H, Pallast S, Mandeville E, Joshi N, Smirnova N, Gazaryan I, Ratan RR, Witztum JL, Montaner J, Holman TR, Lo EH, van Leyen K. Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann Neurol. 2013 Jan;73(1):129-35. 183. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng YC,

Fornage M, Ikram MA, Malik R, Bevan S, Thorsteinsdottir U, Nalls MA, Longstreth W, Wiggins KL, Yadav S, Parati EA, Destefano AL, Worrall BB, Kittner SJ, Khan MS, Reiner AP, Helgadottir A, Achterberg S, Fernandez-Cadenas I, Abboud S, Schmidt R, Walters M, Chen WM, Ringelstein EB, O'Donnell M, Ho WK, Pera J, Lemmens R, Norrving B, Higgins P, Benn M, Sale M, Kuhlenbäumer G, Doney AS, Vicente AM, Delavaran H, Algra A, Davies G, Oliveira SA, Palmer CN, Deary I, Schmidt H, Pandolfo M, Montaner J, Carty C, de Bakker PI, Kostulas K, Ferro JM, van Zuydam NR, Valdimarsson E, Nordestgaard BG, Lindgren A, Thijs V, Slowik A, Saleheen D, Paré G, Berger K, Thorleifsson G; The Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2), Hofman A, Mosley TH, Mitchell BD, Furie K, Clarke R, Levi C, Seshadri S, Gschwendtner A, Boncoraglio GB, Sharma P, Bis JC, Gretarsdottir S, Psaty BM, Rothwell PM, Rosand J, Meschia JF, Stefansson K, Dichgans M, Markus HS; on behalf of the International Stroke Genetics Consortium. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11(11):951-962.

184. Ní Chróinín D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Díez-Tejedor E, Di Napoli M, Engelter ST, Furie KL, Giannopoulos S, Gotto AM Jr, Hannon N, Jonsson F, Kapral MK, Martí-Fàbregas J, Martínez-Sánchez P, Milionis HJ, Montaner J, Muscari A, Pikija S, Probstfield J, Rost NS, Thrift AG, Vemmos K, Kelly PJ. Statin Therapy and Outcome After Ischemic Stroke: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials. Stroke 2013;44(2):448-456.

184. Riba-Llena I, Montaner J, Delgado P; on behalf of the ISSYS project. Letter by Riba-Llena et al Regarding Article, "Not Listened or Not Reported Rather Than Silent Stroke". Stroke. 2013;44(4):e42


23

185. Massot A, Navarro-Sobrino M, Penalba A, Arenillas JF, Giralt D, Ribó M, Molina C, Alvarez-Sabín J, Montaner J, Rosell A. Decreased levels of angiogenic factors in intracranial atherosclerotic disease despite severity-related increase in endothelial progenitor cell counts. Cerebrovascular Diseases 2013;35(1):81-8.

186. Rosell A, Agin V, Rahman M, Morancho A, Ali C, Koistinaho J, Wang X, Vivien D, Schwaninger M, Montaner J. Distal occlusion of the middle cerebral artery in mice: Are we ready to assess long-term functional outcome? Translational Stroke Research 2013;4(3):297-307.

187. Anderson CD, Biffi A, Nalls MA, Devan WJ, Schwab K, Ayres AM, Valant V, Ross OA, Rost NS, Saxena R, Viswanathan A, Worrall BB, Brott TG, Goldstein JN, Brown D, Broderick JP, Norrving B, Greenberg SM, Silliman SL, Hansen BM, Tirschwell DL, Lindgren A, Slowik A, Schmidt R, Selim M, Roquer J, Montaner J, Singleton AB, Kidwell CS, Woo D, Furie KL, Meschia JF, Rosand J; on behalf of the International Stroke Genetics Consortium. Common Variants within Oxidative Phosphorylation Genes Influence Risk of Ischemic Stroke and Intracerebral Hemorrhage. Stroke 2013 ;44(3):612-9.

188. Salat D, Penalba A, García-Berrocoso T, Campos-Martorell M, Flores A, Pagola J, Bustamante A, Quintana M, Giralt D, Molina C, Alvarez-Sabín J, Montaner J. Immunological biomarkers improve the accuracy of clinical risk models of infection in the acute phase of ischemic stroke. Cerebrovascular Diseases 2013;35(3):220-227.

189. Fernandez-Morales J, Penalba A, Rubiera M, Hernandez-Guillamon M, Rosell A, Delgado P, Chacon P, Ribo M, Alvarez-Sabin J, Molina CA, García-Arumi E, Montaner J. Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics 2013;14(5):495-504.

190. Navarro-Sobrino M, Hernández-Guillamon M, Fernandez-Cadenas I, Ribó M, Romero IA, Couraud PO, Babette Barbash Weksler, Montaner J, Rosell A. The angiogenic gene profile of circulating endothelial progenitor cells from ischemic stroke patients Vascular Cell 2013;5(1):3.

191. Cucchiara B, Montaner J. Blood biomarkers for predicting outcome after stroke: Reading the tea leaves. Neurology. 2013;80(14):1270-1.

192. Rodriguez-Luna D, Piñeiro S, Rubiera M, Ribo M, Coscojuela P, Pagola J, Flores A, Muchada M, Ibarra B, Meler P, Sanjuan E, Hernandez-Guillamon M, Álvarez-Sabín J, Montaner J, Molina C. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. European Journal of Neurology. 2013 (in press)

193. Devan WJ, Falcone GJ, Anderson CD, Jagiella JM, Schmidt H, Hansen BM, Jimenez-Conde J, Giralt-Steinhauer E, Cuadrado-Godia E, Soriano C, Ayres AM, Schwab K, Kassis SB, Valant V, Pera J, Urbanik A, Viswanathan A, Rost NS, Goldstein JN, Freudenberger P, Stögerer EM, Norrving B, Tirschwell DL, Selim M, Brown DL, Silliman SL, Worrall BB, Meschia JF, Kidwell CS, Montaner J,


24

Fernandez-Cadenas I, Delgado P, Greenberg SM, Roquer J, Lindgren A, Slowik A, Schmidt R, Woo D, Rosand J, Biffi A; on behalf of the International Stroke Genetics Consortium. Heritability Estimates Identify a Substantial Genetic Contribution to Risk and Outcome of Intracerebral Hemorrhage. Stroke. 2013 Apr 4.[Epub ahead of print] PubMed PMID: 23559261.

194. Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, Ois A, Rodríguez-Campello A, Cuadrado-Godia E, Fernández-Cadenas I, Montaner J, Lucas G, Elosua R, Roquer J; GeneStroke “The Spanish Stroke Genetics Consortium”. DNA Isolation Method Is a Source of Global DNA Methylation Variability Measured with LUMA. Experimental Analysis and a Systematic Review. PLoS One. 2013;8(4):e60750.

195. Bustamante A, Montaner J. Statin Therapy Should Not be Discontinued in Patients With Intracerebral Hemorrhage. Stroke. 2013;44(7):2060-1.

196. Carenza E, Barceló V, Morancho A, Levander L, Boada C, Laromaine A, Roig A, Montaner J, Rosell A. In vitro Angiogenic Performance and in vivo Brain Targeting of Magnetized Endothelial Progenitor Cells for Neurorepair Therapies. Nanomedicine. 2013 Jun 19. [Epub ahead of print] PubMed PMID: 23792330.

197. Morancho A, Hernández-Guillamon M, Boada C, Barceló V, Giralt D, Ortega L, Montaner J, Rosell A. Cerebral ischaemia and matrix metalloproteinase-9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. J Cell Mol Med. 2013 Aug 15. [Epub ahead of print] PubMed PMID: 23945132.

198. Rosell A, Morancho A, Navarro-Sobrino M, Martínez-Saez E, Hernández-Guillamon M, Lope-Piedrafita S, Barceló V, Borrás F, Penalba A, García-Bonilla L, Montaner J. Factors secreted by endothelial progenitor cells enhance neurorepair responses after cerebral ischemia in mice. PLoS One 2013;8(9):e73244.

199. Giralt-Steinhauer E, Jiménez-Conde J, Soriano Tárraga C, Mola M, Rodríguez-Campello A, Cuadrado-Godia E, Ois A, Fernández-Cádenas I, Carrera C, Montaner J, Díaz Navarro RM, Vives-Bauzá C, Roquer J. Exploring the genetic basis of stroke. Spanish stroke genetics consortium. Neurologia. 2013 Jul 4. [Epub ahead of print] PubMed PMID: 23831412.

200. Malhotra S, Castilló J, Negrotto L, Merino-Zamorano C, Montaner J, Vidal-Jordana A, Montalban X, Comabella M. TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients J Neuroimmunol. 2013 (in press)

201. Bustamante A, et al. Prognostic Value Of Plasma Chitotriosidase Activity In Acute Stroke Patients. International Journal of Stroke. 2013 (in press)

202. Hernández-Guillamon M, Ortega L, Merino-Zamorano C, Campos-Martorell M, Rosell A, Montaner J.


25

Mild hypothermia protects against oxygen glucose deprivation (OGD)-induced cell death in brain slices from adult mice. Journal of Neural Transmission. 2013 Sep 14. [Epub ahead of print]

203. Campos M, García-Bonilla L, Hernández-Guillamon M, Barceló V, Morancho A, Quintana M, Rubiera M, Rosell A, Montaner J. Combining statins with tPA treatment after experimental and human stroke: a safety study on hemorrhagic transformation. CNS Neurosci Ther. 2013 Nov;19(11):863-70.

204. García-Berrocoso T, García-Berrocoso T, Penalba A, Boada C, Giralt D, Cuadrado E, Colomé N, Dayon L, Canals F, Sanchez JC, Rosell A, Montaner J. From brain to blood: new biomarkers for ischemic stroke prognosis. Journal of Proteomics. 2013 Sep 20.

205. Riba-Llena I, Jarca CI, Mundet X, Tovar JL, Orfila F, López-Rueda A, Nafría C, Fernández JL, Castañé X, Domingo M, Alvarez-Sabín J, Fernández-Cortiñas I, Maisterra O, Montaner J, Delgado P. Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. BMC Neurol. 2013 Oct 2;13(1):130.

206. Bosutti A, Qi J, Pennucci R, Bolton D, Matou S, Ali K, Tsai LH, Krupinski J, Petcu EB, Montaner J, Al Baradie R, Caccuri F, Caruso A, Alessandri G, Kumar S, Rodriguez C, Martinez-Gonzalez J, Slevin M. Targeting p35/Cdk5 Signalling via CIP-Peptide Promotes Angiogenesis in Hypoxia. PLoS One. 2013 Sep 30;8(9):e75538.

Review Articles.

1. Montaner J, Alvarez-Sabin J. ¿Se ha modificado la epidemiología del infarto cerebral? Ictus www.ictus.org 22-12-97.

2. Montaner J, Alvarez-Sabin J. Protocolo diagnóstico diferencial del síndrome confusional agudo en el paciente con antecedentes de etilismo. Medicine 1998;7(1):4539-4542.

3. Montaner J, Alvarez-Sabín J. Neuroimagen en el ictus isquémico. Neurología 1999;14 (supl 2):13-21.

4. Alvarez-Sabín J, Montaner-Villalonga J. Antiagregación plaquetaria en la prevención secundaria del ictus después del ESPS-2 y del CAPRIE. Rev Neurol 1999;29:780-784.

5. Montaner J, Alvarez-Sabín J. Manifestaciones neurológicas en la enfermedad de Fabry. Clínica Nefrológica 2002;1:20-22.

6. Rosell A, Montaner J, Alvarez-Sabín J. El papel de la angiogénesis en isquemia cerebral. Rev Neurol 2004; 38(11):1076-82.


26

7. Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Review of Neurotherapeutics 2005;5(2):211-221.

8. Montaner J. Latest advances and research in stroke: Focus on diagnostic and therapeutic targets. Drug News Perspect 2006;19(3): 173-83.

9. Montaner J. Latest advances and research in stroke: highlights from the 31st International Stroke Conference. Timely Top Med Cardiovasc Dis. 2006 Jul 1;10:E16. 10. Montaner J. Stroke biomarkers: Can they help us guide stroke thrombolysis?. Drug News Perspect. 2006 Nov;19(9):523-532. 11. Montaner J. Reflexiones sobre la armonización de estándares para el deterioro cognitivo de origen vascular NINDS-CSN. Alzheimer. Realidades e investigación en demencia 2007;36: (in press). 12. Cuadrado E, Rosell A, Montaner J. Captura por microdisección láser: una nueva herramienta para el estudio de la isquemia cerebral. Rev Neurol 2007;44(9):551-555. 13. Montaner J. Latest Advances and Research in Stroke Treatment 2007. Drug News Perspect 2007 April;20(3):197-208. 14. Montaner J. Stroke biomarkers: can they help us to guide stroke thrombolysis? Timely Top Med Cardiovasc Dis. 2007 Apr 9;11:E11. 15. Delgado P, Alvarez Sabin J, Montaner J. Biological markers in spontaneous intracerebral hemorrhage. Neurologia. 2007;22(7):448-55. 16. Navarro M, Rosell A, Hernández-Guillamon M, Cuadrado E, Montaner J. Potencial terapéutico de las células progenitoras endoteliales (CPEs) en el ictus isquémico. Rev Neurol. 2007;45(9):556-62. 17. Domingues-Montanari S, Mendioroz M, del Rio A, Fernández-Cadenas I, Montaner J. Genetics of Stroke: A Review of Recent Advances. Expert Rev Mol Diagn. 2008 Jul;8(4):495-513. 18. del Río-Espínola A, Mendióroz M, Domingues-Montanari S, Pozo-Rosich P, Solé E, Fernández-Morales J, Fernández-Cadenas I, Montaner J. CADASIL management or what to do when there is little one can do. Expert Rev Neurother. 2009;9(2):197-210. 19. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Searching for oracles? Blood biomarkers in acute stroke Neurology. 2009;73(5):393-9. 20. Montaner J. Blood biomarkers to guide stroke thrombolysis. Front Biosci (Elite Ed). 2009 Jun 1;1:200-208.


27

21. Mendioroz M, Cuadrado E, Montaner J. Biomarcadores plasmáticos en la enfermedad vascular cerebral isquémica Hipertensión y riesgo vascular. 2009 (in press). 22. Salat D, Ribosa R, Garcia-Bonilla L, Montaner J. Statin Use Before And After Acute Ischemic Stroke Onset Improves Neurological Outcome. Expert Review of Cardiovascular Therapy 2009;7(10):1219-30. 23. Del Río Espínola A, Solé E, Montaner J. Pathophysiology of CADASIL disease. Med Clin (Barc). 2009 Dec 24. [Epub ahead of print] 24. García-Berrocoso T, Fernández-Cadenas I, Delgado P, Rosell A, Montaner J. Blood Biomarkers in Cardioembolic Stroke. Curr Cardiol Rev. 2010;6(3):194-201 25. García-Berrocoso T, Fernández-Cadenas I, Delgado P, Rosell A, Montaner J. Blood Biomarkers to Identify Stroke Etiologies. Therapy 2010 (in press). 26. Tovar J.L., Delgado P, Montaner J. Manejo de la hipertensión arterial en el ictus NefroPlus 2010;3(1):39-50 27. Morancho A, Rosell A, García-Bonilla L, Montaner J. Metalloproteinase and Stroke Infarct Size: Role for Anti-Inflammatory Treatment? Ann N Y Acad Sci. 2010;1207:123-33 28. García-Bonilla L, Rosell A, Torregrosa G, Salom JB, Alborch E, Gutiérrez M, Díez- Tejedor E, Martínez-Murillo R, Agulla J, Ramos-Cabrer P, Castillo J, Gasull T, Montaner J. Guía de recomendaciones en la aplicación de modelos animales para el estudio del ictus. Neurologia. 2011;26(2):105-110. 29.- Nafria C, Fernández-Cadenas I, Mendioroz M, Domingues-Montanari S, Hernandez-Guillamon M, Fernández-Morales J, del Río-Espinola A, Giralt D, Deu L, Delgado P, Rosell A, Montaner J. Update of biomarkers and genetic factors associated with safety and efficacy of rt-PA treatment in acute stroke patients. Stroke Research and Treatment. 2011:182783. Epub 2011 Jun 9. 30.- Salat D, Campos M, Montaner J.

Avances en la fisiopatología y manejo de las infecciones en la fase aguda del ictus.

Medicina Clínica. 2012 (en prensa). 31.- Florczak-Rzepka M, Grond-Ginsbach C, Montaner J, Steiner T. Matrix Metalloproteinases in Human Spontaneous Intracerebral Hemorrhage: An Update. Cerebrovasc Dis. 2012;34(4):249-262. 32.- Lemarchant S, Pruvost M, Montaner J, Emery E, Vivien D, Kanninen K, Koistinaho J. ADAMTS proteoglycanases in the physiological and pathological central nervous system. Journal of Neuroinflammation 2013 (in press)


28

BOOK CHAPTERS: 1. Ictus en la mujer post-menopáusica y acción preventiva de los estrógenos.

Alvarez-Sabín J, Montaner J, Molina C. En: Post-menopausia y enfermedad cardiovascular. Ed. A. Cabero Roura. Springer-Verlag Ibérica, Barcelona 1998.

2. Ictus. Reto de la investigación para el próximo siglo. Alvarez-Sabín J, Abilleira S, Montaner J. En: El ensayo clínico en neurología. Ediciones Ergon. Madrid 1999.

3. Ictus cardioembólico. Alvarez-Sabín J, Molina C, Dávalos A, Rubio F, Montaner J. En: Protocolos Diagnóstico-Terapéuticos en Patología Cerebrovascular. Grupo de estudio de enfermedades cerebrovasculares de la SEN.1999.

4. Estudio de la reserva cerebral: implicaciones clínico-terapéuticas. Molina C, Abilleira S, Montaner J. En: Actualización diagnóstica y terapéutica de la isquemia cerebrovascular. Coordina M. Matas Docampo y J. Alvarez Sabín

5. Objetivos y método de la investigación bibliográfica. Alvarez-Sabín J, Montaner J, Gonzalez-Sanchez MA, Casado L. En: Técnicas de Investigación en Patología Cerebrovascular. Coordinador: Prof. J. Castillo. EdiDe 2001, Barcelona.

6. Nuevas líneas de investigación de hemostasia y trombosis en patología cerebrovascular. Monasterio J, Anglés A, Alvarez-Sabín J, Montaner J, Abilleira S, Molina C, Nicolau C, Codina A. En: Técnicas de Investigación en Patología Cerebrovascular. Coordinador: Prof. J. Castillo. EdiDe 2001, Barcelona.

7. Hemorragia intracerebral. Abilleira S, Montaner J, Alvarez-Sabín J. En: Patología cerebrovascular hemorrágica. Coordinador: José Alvarez-Sabín. Publicaciones Permanyer 2001, Barcelona. 8. Patología cerebrovascular isquémica. Alvarez-Sabín J, Molina C, Abilleira S, Montaner J. En: Patología cerebrovascular isquémica. Coordinador: José Alvarez-Sabín. Publicaciones Permanyer 2001, Barcelona. 9. Integración de los factores genéticos en la demencia vascular.

Fernández I, Montaner J, Alvarez-Sabín J. En: Jiménez MD, Moreno J, Iriarte LM (Eds.). Ictus y Demencia Vascular. 2003.

10. La cascada isquémica. Marcadores de progresión del ictus. Alonso de Leciñana M, Vila N, Montaner J.

En: A. Gil y cols (Ed.) Medicina cardiovascular. Arteriosclerosis. Ed Masson S.A. Barcelona 2005. 11. Isquemia cerebral global.

Alvarez-Sabín J, Montaner J. En: Martí-Vilalta JL (Ed). Enfermedades Vasculares Cerebrales (2ª edición) 2004.

12. Matrix metalloproteinases (MMPs) and tissue plasminogen activator (t-PA) reperfusion therapy for stroke.


29

Ning MM, Montaner J, Lo EH. En: Chan P (Eds.). Handbook of Neurochemistry. 2005 (in press) 13. Exploraciones complementarias en el paciente con ictus y cancer. Montaner J, Perea-Gainza M. En. Arboix A (Ed). Métodos Diagnósticos en las Enfermedades Vasculares Cerebrales, 2ª edición 2006 (en prensa) 14. Biomarcadores. Montaner J, Rosell A. En. Arboix A (Ed). Métodos Diagnósticos en las Enfermedades Vasculares Cerebrales, 2ª edición 2006 (en prensa) 15. Molecular signatures of course and prognosis of intracerebral hemorrhage. Montaner J, Rodríguez-Yáñez M, Castellanos M, Álvarez-Sabín J, Castillo J. En: Seminars in Cerebrovascular Diseases and Stroke. “Update in intracerebral hemorrhage” 2005; 5:178-188. 16. The neurovascular unit concept Rosell A, Ning M, Montaner J, Wang X, Lo E.H. En: Montaner J (Ed). Fisiopatología de la Isquemia Cerebral. 1ª edición 2007. 17. Biomarcadores inflamatorios y genéticos En. Arboix A y Grau-Olivares M (Ed). Deterioro Cognitivo de Tipo Vascular 2008 BOOKS: 1. Mitos en Ictus. Montaner J, Perea M, Álvarez-Sabín J. Mayo Ediciones 2006 2. Fisiopatología de la Isquemia Cerebral. Montaner J. Marge Médica Books 2007 3. Prevención del Ictus Isquémico. Montaner J. Marge Médica Books 2008 4. Tratamiento del Ictus Isquémico. Montaner J. Marge Médica Books 2009 5. Ataque Isquémico Transitorio. Montaner J. Marge Médica Books 2009 6. Neurorreparación y Rehabilitación tras el Ictus. Montaner J. Marge Médica Books 2010 7. Ictus Lacunar. Montaner J. Marge Médica Books 2012


30

INVITED PROFESSOR (International Conferences): Fibrinolysis in stroke treatment. (Tratamento por Re-Permeabilizaçao). VII jornadas de medicina interna do centro hospitalar do Funchal. Madeira 2-4 Março 2000. Metalloproteinases and Acute Cerebral Ischemia in Humans Sesiones del Neuroprotection Research Laboratory. Charlestown, MA.16th July 2004. The role of matrix metalloproteinases in ischemic stroke. Meetings of the MGH Stroke Unit. Massachusetts General Hospital. Boston, MA. 22th September 2004. Novos marcadores biológicos de doença vascular. Conferencia de clausura de la 20ª Reunião do Grupo de Estudo das Doenças Cerebrovasculares e 1ª da Sociedade Portuguesa do Acidente Vascular Cerebral. Sesimbra, 30 de Abril de 2005. Anoxo-ischemic encephalopathy and other types of global cerebral ischemia. Etiology and treatment. Iberoamerican Symposium: Cerebral ischemia in special conditions. 14th European Stroke Conference. Bologna, Italy 25 - 28 may, 2005 Markers of growth in intracerebral hemorrhage. Intracerebral hemorrhage – further knowledge and future treatment. 14th European Stroke Conference. Bologna, Italy 25 - 28 may, 2005 An introduction to biomarkers in acute stroke. A new paradigm in emergency stroke diagnosis. 14th European Stroke Conference. Bologna, Italy 25 - 28 may, 2005 Stroke Biomarkers: Clinical Utilities. INVIDIS study group meeting. Geneve 28th July 2005. Biochemical markers towards integration: Transient Ischemic Attack and Stroke. 1st International Course, Integrated Biomarkers, Biochemical and Bioimaging Endpoints in Cardiocerebrovascular Diagnosis, Prevention, Therapy and Drug Development. Lugano (Switzerland), October 27-29, 2005. Biomarkers to guide stroke thrombolysis. Sesiones del Equipe INSERM-Avenir “t-PA in the working brain” GIP Cyceron, Université de Caen, France, 26 Enero 2006. Biomarkers to guide safety and efficacy of stroke thrombolysis. 19th International Congress on Thrombosis. Tel Aviv, Israel, May 16th 2006. Transient ischemic attack and stroke: the usefulness of biochemical markers. 38º Congresso Nazionale Società Italiana di Biochimica Clinica e Biologia Molecolare. Torino, Italy 20 de Septiembre de 2006.


31

Biochemical monitoring of acute ischemic stroke. International symposium acute stroke therapy: an update. Santiago de Compostela 21 y 22 de Septiembre de 2006. Marcadores Inflamatorios de la Enfermedad Cerebrovascular. LXI Congreso Chileno de Neurología, Psiquiatría y Neurocirugía. “Neurociencias: de la molécula a la mente”. La Serena, Chile. 2-4 de Noviembre de 2006. Marcadores Bioquímicos de la Enfermedad Cerebrovascular. LXI Congreso Chileno de Neurología, Psiquiatría y Neurocirugía. “Neurociencias: de la molécula a la mente”. La Serena, Chile. 2-4 de Noviembre de 2006. Marcadores Moleculares en el Crecimiento de los Hematomas. LXI Congreso Chileno de Neurología, Psiquiatría y Neurocirugía. “Neurociencias: de la molécula a la mente”. La Serena, Chile. 2-4 de Noviembre de 2006. Novas variáveis de avaliação nos ensaios clínicos em Neuroprotecção. Oporto, Portugal. 1 de Febrero de 2007 Acute and chronic temporal profiles of C-reactive protein after human stroke. San Francisco, CA, International Stroke Conference 2007. Proteomics in clinical stroke. 23rd International Symposium on Cerebral Blood Flow, Metabolism & Function (Brain07). May 20th, 2007 Osaka, Japan. The molecular pathology of intracerebral hemorrhage and neuroprotection. Scientific Symposium: Status and trends in the management of acute hemorrhagic stroke. European Stroke Conference, Thursday, May 31 2007, Glasgow, UK. Molecular markers of brain repair. Therapeutic targets. Symposium: From neuroprotection to new repairing stategies in stroke management. European Stroke Conference, Friday, 1st June 2007, Glasgow, UK. Molecular pathology of intracerebral hemorrhage: a chance for neuroprotection?. Conference at MGH, invited by the Neuroprotection Research Laboratory. Charlestown, Boston MA.18th June 2007. The search of biomarkers of acute stroke. EUSI Stroke Summer School June 27th 2007, Barcelona. Stroke Biomarkers: may they help us to guide stroke thrombolysis? Inaugural International Conference on Advances in Cerebrovascular Disease Manchester Metropolitan University, UK, 6th July 2007. The mode of action of diyridamole – beyond antiplatelet effects. Leading Stroke Experts Workshop: Future perspectives in modern stroke management. Warsaw, Poland, 21st – 23rd September 2007 Stroke Biomarkers and Thrombolysis


32

Universidad Fluminense de Niteroi, Rio de Janeiro, Brasil 16th October 2007. Stroke Biomarkers. VI Brazilian Stroke Conference, Joinville (Santa Catarina). 18th October 2007. Stroke Services Organization: Spain. VI Brazilian Stroke Conference, Joinville (Santa Catarina). 19th October 2007. Neurovascular Unit Protection. VI Brazilian Stroke Conference, Joinville (Santa Catarina). 20th October 2007. Prediction of short-term outcome Teaching courses for the European Stroke Conference 13th May Nice, France Predictive Biomarkers in Ischemic Stroke: May we control them with statins? Congrès Annuel Nouvelle Société Française d’Atherosclérose, 13 de Junio de 2008, Biarritz, France. Future therapies in Stroke EUSI-ESO Summer School 23rd June 2008 Lausanne/Morges, Switzerland Neurodegeneration, neuroplasticity and neurogenesis. EUSI-ESO Summer School 23rd June 2008 Lausanne/Morges, Switzerland Biomarkers: A window to the brain. 6th World Stroke Congress, 27th September, 2008 Vienna, Austria Experimental basis for future acute stroke therapies. Austrian Stroke Meeting 31st January, 2009 Donau-Universität Krems. Can proteomics help us optimize stroke therapies? International Stroke Conference 18th February, 2009 San Diego, Ca, US Lp-PLA2 prognostic value during the acute phase of stroke ESC, Stokholm, Sweden 28 May 2009. Poor stroke outcome among women: sexism or dimorphism? First Picastrokemeeting, Caen, September 30th 2009. “Biochemical Markers of Stroke” in the Master Program of Cerebrovascular Medicine at the Charité in Berlin, 27th January 2010. “Metalloproteinase and Stroke Infarct Size: Role for Anti-Inflammatory Treatment?” at the The New York Academy of Sciences, within the symposium “Innate Inflammation as the Common Pathway of Risk Factors Leading to Transient Ischemic Attacks and Stroke: Pathophysiology and Potential Interventions”, New York, US, May 9-10, 2010.


33

”Biomarkers in stroke” within the symposium “Recent developments and future directions in stroke management and prevention”; European Stroke Conference, Barcelona, May 25, 2010 ”Lp-PLA2 prognostic value during the acute phase of stroke” within the symposium “The role of Lp-PLA2 in TIA and stroke in acute care settings”; European Stroke Conference, Barcelona, May 27, 2010 ”Antiplatelet agents, inflammatory biomarkers and acute ischemic stroke” within the symposium “Neuroinflammation and its impact in acute ischemic stroke and Alzheimer disease”; European Stroke Conference, Barcelona, May 27, 2010 ”Fever and inflammation in stroke” within the symposium “Stroke and Body Temperature”; European Stroke Conference, Barcelona, May 28, 2010 “Translational neuroscience in the UAB hospitals” en la International Medical Research Association IMRA 2011 Conference. 17-18 Febrero 2011, Daegu, Korea. “Biochemical Markers of Stroke” in the Master Program of Cerebrovascular Medicine at the Center for Stroke Research Berlin (CSB), 16 Marzo 2011, Berlin, Germany. “Biomarkers in acute stroke. What the blood tells you about the brain…” at the sessions of the Neuroscience Department, Charité Hospital, 17 Marzo 2011, Berlin, Germany. “Genetics of intracerebral haemorrhage” within the symposium “Advances in intracerebral haemorrhage”; European Stroke Conference, Hamburg, May 27, 2011. “Estado Actual de los tratamientos Neuroprotectores en el Infarto Cerebral Agudo” en el XI Congreso Asociación Mexicana de Enfermedad Vascular Cerebral, Villahermosa de Tabasco, Mexico, 27th August, 2011. “Stroke Biomarkers” and chairman of the session entitled "CNS" at the combined HUPO 10th Annual World Congress, 5th EuPA Annual Scientific Meeting and the 8th SPS scientific meeting held in Geneva, Switzerland, from the 4 - 7 September, 2011 “Biomarkers for stroke risk stratification” in the session “Enter at your own risk: carotid revascularization and risk stratification” of the 2nd Canadian Stroke Congress, 2-5 October 2011, Ottawa, Canada. “Vascular diseases: epidemiology, causes, risk factors and demographics in the European population” and “Ischemic stroke: basic pathophysiology and medical management” at the Pierre Lasjaunias ECNR - 11th Cycle, 3rd Course “Vascular Diseases" – Tarragona (Spain), 28 octubre 2011. “Do Biomarker have a potential in predicting stroke diagnosis and stroke outcome?” at the “International workshop on „Biomarkers in Cerebrovascular Diseases“; Inselspital, University of Berne, Switzerland. November 21, 2011. Keynote lecture “Biomarkers in stroke” in the 1st European Stroke Science Workshop at Garmisch-Partenkirchen, Germany. December 16, 2011.


34

“Triflusal in Acute Stroke” and “Triflusal in Guidelines” within the symposium “Triflusal in ischemic stroke: Tips and tricks for prevention and treatment”. Centro Cultural de Belem, Lisbon, May 23, 2012 “Towards a Biochemical Diagnosis of Stroke” at the Academic Symposium “New developments in stroke research” held at the European Stroke Conference, Lisbon, May 24, 2012 “Novel insights into intracerebral hemorrhage - bench to bedside and reverse.” In the session Young Stroke Physicians: Perspectives in translational stroke research, held at the European Stroke Conference, Lisbon, May 24 2012 “Traslational Neuroscience in Barcelona” and “Biomarkers in Stroke and Neurodegeneration” at the International Medical Research Association (IMRA) 2012 Conference, June 28-29 Kobe, Japan ”Biomarkers for neurodegenerative/neurovascular diseases” Caen, France 26th of september. 2012 “Detecting CAA: Biomarkers in plasma and CSF” 3rd International CAA Conference, Leiden 25th october, 2012 “Biomarqueurs et AVC” Sesión plenaria de la SFNV - 17 emes Journées, 22nd november Paris 2012 Plenary Lecture: Biomarkers in human stroke – Applicable to animal models. At the Post-Graduate Course “MODELLING CEREBROVASCULAR DISEASE” Organized and supported by ARISE European Union Collaborative Project; Protea ERA-NET Neuron Program; Doctoral Program of Molecular Medicine, University of Eastern Finland; Biocenter Kuopio; A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio Campus, Finland. March 15-16, 2013 “Biomarkers” European Stroke Network consortium meeting: ESN Stroke Progress Review [Challenges, ESN contribution, opportunities, barriers]. Manchester, 17th-19th April 2013. “Biomarkers in predicting stroke diagnosis and outcome”. First Affiliated Hospital of Zhengzhou University, Zhengzhou China May 18 2013 “Stroke biomarkers: clinical indications” at the XXVIth International Symposium on Cerebral Blood Flow, Metabolism and Function. Shanghai, China, May 20, 2013. “Translational neuroscience in the UAB hospitals”. First Affiliated Hospital of Wenzhou Medical College, China, May 2013 “Still no neuroprotection-related drug working. Why?” Wenzhou Medical College, China, May 2013 "Barcelona Stroke Research Program: the lab-clinics-society connection at Vall d'Hebron Hospital." Brno, República Checa 14, Junio 2013. “Biochemical Markers of Stroke” in the Master Program of Cerebrovascular Medicine at the Center for Stroke Research Berlin (CSB), 12th September 2013, Berlin, Germany.


35

ORGANIZATION OF SCIENTIFIC COURSES AND CONGRESSES: - Annual “Course of Neurovascular Research” within the Doctorate Courses of the Autonomous University of Barcelona, held in Barcelona from 2002 to 2009. - I Course “Actualization in diagnostic and therapeutic techniques for Stroke”. Sevilla, 21-22nd Octuber 2005. - Simposium of the Neurovascular Diseases Group of the Sociedad Española de Neurología. “Nuevas dianas terapéuticas en el Ictus”. Barcelona 23rd November 2005. - Neurovascular genetics simposiums within the anual meetings of the Sociedad Española de Neurología. Barcelona, 2008-2009 - Barcelona Think Tank “Stroke models” [17-18 July 2009]. - XXXI congress of the Spanish Group of Neurotransmision (GEN) [16-18 December 2010]. - Local Organizing Committee of the 19th European Stroke Conference (ESC) [Barcelona-May 2010]. - Local Organizing Committee of the XXVth International Symposium on Cerebral Blood Flow, Metabolism and Function and the Xth International Conference on Quantification of Brain Function with PET [Barcelona-May 2011]. - Co-organizer of the Symposium “Mechanisms of Synaptic Dysfunction in Neurodegenerative Disorders” between the Universitat Autònoma of Barcelona Neuroscience Institute and the Area of Neuroscience- Vall d’Hebron Institute of Research http://www.brainc.eu/ [8-9 July, 2011]. - Member of the organizing committee for the 3rd international conference on Cerebral Amyloid Angiopathy, 24-26 October at the Leiden University Medical Center. 2012. - Member of the organizing committee for the XXVIth International Symposium on Cerebral Blood Flow, Metabolism and Function and the XIth International Conference on Quantification of Brain Function with PET held in Shangai in May 2013. - [Co-Organizing and co-chairing with Dr. MingMing Ning (Boston, MA) a Teaching Course on “Stroke Biomarkers” on behalf of the Scientific Program Committee at that meeting]. Organizer of the international meeting of the consortia PROTEA-ERANET, Barcelona 18th-20th September 2013.


36

CLERKSHIPS AND FOREIGN CENTERS STAGES: 1.-Department of Neurology and Psychiatry. University of Debrecen. Hungary.

August-September 1991.

2.-Medical Department. Glostrup Hospital. Denmark. August 1992.

3.-Department of Pediatrics. Dokuz Eylul University. Izmir. Türkiye.

July-August 1993.

4.-2nd European Stroke Summer School. Heidelberg-Mannheim. Germany. July 1998.

5.-Neuroprotection Research Laboratory, MGH, Harvard University, Boston, MA. July-

October 2004

RESEARCH GRANTS: Completed Research Support Grant of the Spanish Society of Neurology (1999) for cerebrovascular diseases and dementia for the project: “Adhesion molecules and ischemic stroke. Relation between ICAM-1 and arterial reperfusion”. Grant of the Catalan Society of Neurology (2000) “Metalloproteinases in ischemic stroke. The role of MMP-2 and MMP-9 in hemorrhagic transformation”. Co-investigator of the Spanish FIS (Fondo de Investigaciones Sanitarias) grant 01/1389 “Metalloproteinases and brain hemorrhage”. Principal investigator of the Spanish FIS (Fondo de Investigaciones Sanitarias) grant 02/0773 “Role of metalloproteinases in bleeding complications following thrombolytic treatments for ischemic stroke”. Co-investigator of the Spanish FIS (Fondo de Investigaciones Sanitarias) grant 02/0852 “Fabry´s disease: Diagnosis and response to enzymatic therapy. In vitro studies of pathogenic cellular mechanisms”. Research nets: G03/054 Network for the study of unherited metabolic diseases (REDEMETH). Catalan Society of Neurology. Beca Uriach 2004. “Risk Haplotypes for Cerebral Amiloid Angiopathy”. Co-investigator of the Neuroscience Research Grant 2005, from the Maphre Foundation. “Inflammatory response among patients with severe Traumatic Brain Injury. A new therapeutic target?. Principal investigator of the “Consolidated Reaserch Group” given by the Agència de Gestió d’Ajuts Universitaris i de Reçerca, from the Generalitat de Catalunya since October 2005. (Nº expte 614; Grup de Recerca en Malalties Neurovasculars).


37

Principal investigator of the FIS PI 05/322 “Identification of brain ischemia biomarkers by gene expression and proteomics of different cell populations obatined through laser-capture microdissection at the core and penumbra following human stroke.” Principal investigator of the Project: “Geno-tPA: searching genetic patterns to predict clinical evolution among stroke patients treated with t-PA”, funded in 2006 by the “Fundación de Investigación Médica Mutua Madrileña” to support medical research and funded by the Ramón Areces Foundation 2007. Principal investigator of the Project: “GRECOS: genotyping risk of recurrence following stroke” funded by the “Marató de TV3” (06-2610). Principal investigator of the group Vall d’Hebron within the Neurovascular Diseases Network (RENEVAS), at the programme “Tematic networks for Cooperative Health Research (RETICS), 2006-2010. Principal investigator of the Project: MD07/00209 “Study about the causes that generate gender disparities in the neurovascular field: Is stroke a sexist disease?”, funded by ISCIII. Collaborator of the Wellcome Trust project 082496/Z/07/Z, “Cdk5 in cerebral ischemia” Principal investigator of the Project: FIS PI 08/361 “Identification and use of prognostic biomarkers for ischemic stroke” Principal investigator of the Project PI09/90401 “Promoting gender equity in stroke care” funded by ISCIII. Ongoing Research Support Principal investigator of the Project: EC07/90195: “Strategies to improve safety and efficacy of the treatment with Simvastatin in the acute phase of ischemic stroke: STARS trial.”, funded by the ISCIII at the call for non-profit drugs for human use independent research programme. Investigator of the EU project “European Stroke Research Network (EUSTROKE)” from the 7th FP (Health F2-2008-202213). Principal investigator of the Project: EC08/00137: “GRECAS: Genotyping safety and efficacy of Clopidogrel and Aspirin following stroke; towards a personal secondary prevention”, funded by the ISCIII at the call for non-profit drugs for human use independent research programme. Principal investigator of the support programme EUROSALUD-09 to European Projects (EUSTROKE) funded by ISCIII: EUS2008-03610: EUROPEAN STROKE RESEARCH NETWORK. Principal investigator of the Vall d’Hebron Team at the Consorcio de Terapias Neuroreparadoras en Ictus (TNR) funded by ACC1Ó (Gobern de Catalunya).


38

Principal investigator of the “Grupo de Investigación Consolidado” por la Agència de Gestió d’Ajuts Universitaris i de Reçerca, de la Generalitat de Catalunya 2009-2013. Nº expte SGR 432; Grup de Recerca en Malalties Neurovasculars. Principal investigator of the Project EC10-336 “Comparative study on the use of drugs, treatment adherence and blood pressure control in a cohort of hypertensives in the primary healthcare system”, funded by the ISCIII at the call for non-profit drugs for human use independent research programme. Benefitiary of the Programme to Intensify Research Activity at the National Healthcare System (I3 SNS) during 2010 and 2011. Work Package leader of the European Project EUROHYP-1, WP9 Biomarkers (CP-IP 278709-2, FP7-HEALTH-2011-two-stage). Principal investigator of the Project INTRASALUD PI 11/0176 “Stroke Biomarkers: Optimizing the steps in traslation from discovery to routine use.” ERA-NET NEURON Joint Call 2011 [European Research Projects on Cerebrovascular Diseases]: “PROTEA: Influence of proteases before, during and after stroke” Denis Vivien (FR), Jari Koistinaho (FI), Joan Montaner (ES) and José A. Páramo (ES). [PRPPRI-PIMNEU-2011-1352]. PI of the Work Package “Stroke Prevention” in the Spanish stroke research network INVICTUS (RD12/0014/0005) Work Package leader at FP7-603043 Multi-PART Multicentre Preclinical Animal Research TeamTHEME [HEALTH.2013.4.1-4] [Preparing the future for health research and innovation] http://www.camarades.info/Multipart/MPARTfront.html My lab is leading the Spanish national Stroke Genetics network (http://www.genestroke.com/), and we are coordinating the participation of many hospitals in several projects linked to stroke genetics with the collection of multiple biological and clinical data; and we are also participating in the international stroke genetics consortium (http://www.strokegenetics.com/).


39

DIRECTOR of DOCTORAL THESIS: Marc Ribó Jacobi: “Influencia de los inhibidores endógenos de la fibrinolisis sobre el tratamiento trombolítico del ictus con t-PA” Universidad Autónoma de Barcelona, Diciembre 2004. Excelente “cum laude”. Francisco Purroy García: “Marcadores predictores de recurrencia de eventos cardiovasculares tras un AIT.” Universidad Autónoma de Barcelona, Julio 2005. Excelente “cum laude”. Anna Rosell Novell: “Caracterización bioquímica de la isquemia cerebral humana. Distribución de metaloproteasas de matriz en la zona del core y penumbra isquémica.” Universidad Autónoma de Barcelona, Julio 2005. Excelente “cum laude”. Israel Fernández-Cadenas: “Proyecto Geno-tPA: Influencia del background genético en la eficacia y seguridad del tratamiento con t-PA en pacientes con ictus isquémico.” Universidad Autónoma de Barcelona, Julio 2006. Excelente “cum laude”. Pilar Delgado Martinez: “Biomarcadores y haplotipos de riesgo en la hemorragia cerebral producida por angiopatía amiloide” Universidad Autónoma de Barcelona, Septiembre 2006. Excelente “cum laude”. Mila Perea Gainza “Utilidad del empleo de biomarcadores en el diagnóstico etiológico del ictus isquémico” Universidad de Cádiz, Diciembre 2006. Excelente “cum laude”. Eloy Cuadrado Godia “Las metaloproteinasas de matriz en la isquemia cerebral: origen, localización celular y contribución al daño tisular” Universidad Autónoma de Barcelona, 3 Marzo 2009. Excelente “cum laude”. Maite Mendióroz Iriarte “Utilidad de los biomarcadores plasmáticos en el diagnóstico, tratamiento y pronóstico de la enfermedad cerebrovascular aguda” Universidad Autónoma de Barcelona, 1 Junio 2010. Excelente “cum laude”. Miriam Navarro “Influencia de las células endoteliales progenitoras sobre la modulación espacial y temporal de la angiogénesis y vasculogénesis después del ictus isquémico humano” Universidad Autónoma de Barcelona, 29 Julio 2010. Excelente “cum laude”. Sophie Domínguez-Montanari “Identification of genetic risk factors for ischemic stroke“ Universidad Autónoma de Barcelona, 7 de Octubre 2010. Excelente “cum laude”. Alberto del Rio Espinola “Genética aplicada a la clínica neurovascular” Universidad Autónoma de Barcelona, 14 de Febrero 2011. Excelente “cum laude” y mención Europea. Andreu Massot Tarrús


40

“Aterosclerosi intracranial: Marcadors de recurrènca d’esdeveniment isquèmic i gravetat.” Universidad Autónoma de Barcelona, 17 de Junio 2013. Apte “cum laude”. David Salat i Foix “Infecció a la fase aguda de l’ictus: estudi pronòstic i aportacions al diagnòstic precoç.” Universidad Autónoma de Barcelona, 1 de Julio 2013. Apte “cum laude”. Jessica Fernandez Morales “Endofenotips, risc genetic i factors que predisposen a la cronificació de la migranya” Universidad Autónoma de Barcelona, X de Octubre 2013. Apte “cum laude”. AWARDS: From the Catalan Society of Neurology to the best platform presentation at its scientific meetings held in Barcelona the years 1998, 1999 y 2000. From the Spanish Society of Neurology to the best 2001 article about Cerebrovascular Diseases. “Matrix metalloproteinase expression after human cardioembolic stroke. Temporal profile and relation to neurological impairment. Montaner J, et al. Stroke ” From the Spanish Society of Neurology to the best 2002 article about Cerebrovascular Diseases. “Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Montaner J, et al. Stroke ” Young Investigator Award for excellency in stroke research, European Stroke Council. Received at the 12ª European Stroke Conference, held in Valencia, 24th May 2003. Extraordinary award from the Universidad Autónoma de Barcelona to the Doctoral Thesis “The role of Matrix Metalloproteinases in the acute phase of ishemic stroke” and to the publications derived of this thesis. Award for Excellency in stroke research, by its study “Post-stroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis” presented at the 13ª European Stroke Conference, held in Mannheim-Heidelberg, 15th May 2004. Award for the best teaching activity held during the congreso of the Sociedad Española de Neurología 2005, by organizing the Symposium “New therapeutic targets in stroke”.

From the Sociedad Española de Neurología to the best article in Cerebrovascular Diseases 2006. “La escala de ictus de la NIH y su adaptación al español. Montaner J, et al. Neurología ”

Traslational Medicine Award from the Fundación Hospital de Madrid 2007, by the study “Matrix Metalloproteinase (MMP-9) pre-treatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Montaner J, et al. Circulation.”


41

EXTERNAL REVIEWER: Journals American Journal of Hypertension

Annals of Neurology

Arteriosclerosis, Thrombosis and Vascular Biology

Atherosclerosis

Biomarkers in Medicine

BMC Neuroscience

Brain

Brain, Behavior, and Immunity

Brain Research

Cerebrovascular Diseases

Circulation

Clinical Biochemistry

Clinical Chemistry and Laboratory Medicine

Clinical Medicine: Cardiology

European Journal of Clinical Investigation

European Journal of Pharmacology

European Journal of Neurology

European Journal of Neuroscience

European Neurology

Experimental Biology and Medicine

Expert Review of Cardiovascular Therapy

Expert Review of Neurotherapeutics

Expert Review of Molecular Diagnostics

Free Radical Biology & Medicine

Hypertension

International Journal of Stroke

International Journal of Molecular Science

Intensive Care Medicine

Journal of Angiogenesis Research

Journal of Cell Science

Journal of Cellular and Molecular Medicine

Journal of Cerebral Blood Flow and Metabolism

Journal of Leukocyte Biology


42

Journal of Medical Genetics

Journal of the Neurological Sciences

Journal of Neurochemistry

Journal of Neuroinflammation

Journal of Neurology

Journal of Neurotrauma

Journal of Neuroscience Research

Journal of Proteome Research

Lancet

Lancet Neurology

Molecular Psychiatry

Nature Reviews Neurology

Neurodegenerative Diseases

Neurología

Neurological Research

Neurological Sciences

Neurology

Neuropharmacology

Neuroscience Letters

Neurotherapeutics

Plos One

Pharmacological Reports

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

Stroke

Swiss Medical Weekly

The Application of Clinical Genetics

The Lancet Neurology

Thrombosis and Haemostasis

Toxicology


43

International Evaluation Agencies Scientific Advisory Board of the Strategic Research Programme on Stroke 2007 of the Italian Ministry of Health. Biomedical and Therapeutic Research Committee, of the Scottish Chief Scientist Office (Health Department). U.S.-Israel Binational Science Foundation. National Medical Research Council (NMRC) of the Ministry of Health, Singapore. “Populations and Public Health Grants Management Department” and the “Neuroscience and Mental Health Grants Management Department”, The Wellcome Trust, UK, and projects from the “The Stroke Association, UK”. Swiss National Science Foundation (Division of Biology and Medicine). The French National Research Agency (ANR). Review board for the 2012 NEURON joint transnational call “Novel Methods and Approaches towards the Understanding of Brain Diseases”. European Commission. Expert reviewer for the The Institut Clinique de la Souris - ICS (Mouse Clinical Insitute - MCI). Reviewer for the “Research Training Fellowships for Healthcare Professionals” programme of the Health Research Board (HRB) in Ireland. Abstract reviewer for the congresses of the International Society for Cerebral Blood Flow and Metabolism (2005-). Scientific Committee de la European Stroke Conference (2007-) Abstract reviewer for the International Stroke Conference (grade abstracts for ISC 2013 and ISC 2014) Editorial Boards Stroke (since 2007) http://stroke.ahajournals.org/misc/edboard.shtml

Vascular Cell (former Journal of Angiogenesis Research) (since 2009) http://www.vascularcell.com/about/edboard Translational Stroke Research (since 2009) http://www.springer.com/biomed/neuroscience/journal/12975?detailsPage=editorialBoard

Cerebrovascular Diseases (since 2010) http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalEditorial&ProduktNr=224153

and Associate Editor of Translational Proteomics (since 2012) http://www.elsevier.com/wps/find/journaleditorialboard.cws_home/729319/editorialboard


44

SCIENTIFIC SOCIETIES: Member of the Spanish Society of Neurology (SEN). Member of the Spanish Society of Neurosonology (SONES). Member of the Scientific Stroke Council. American Heart Association. Membership in the International Society for Cerebral Blood Flow and Metabolism. Member of the American Heart Association and the American Stroke Association. Member of the Sociedad Española de Neurociencias Member of the World Stroke Organization (WSO) Member of the European Stroke Organization (ESO) Member of the New York Academy of Sciences. Member of the Academia de Ciencias Médicas y de la Salud de Catalunya i Balears. Founder member of the Working Group in Neurochemistry from the Spanish Society of Clinical Biochemistry (SEQC). Member of the PRESARV group (Secondary prevention and high vascular risk) from the Arteriosclerosis Spanish Society (SEA) RESEARCH FOUNDATIONS Founding member of the Spanish Foundation for the diagnosis and study of Fabry’s disease (FEDEF). Founding member of the Mediterranean League Against Thromboembolic Disesases (MLTD) Fundation Founding member of the Foundation for Research in Stroke (FRI-Stroke).


45

STROKE CLINICAL TRIALS Principal investigador ICTUS Study: International Citicoline Trial on Acute Stroke Treatment with citicoline within within 24 hours of their initial stroke symptoms onset.

ASY11714 trial To quantify variation of fibrinolyisis markers including TAFIa/TAFIai, in patients with acute ischemic stroke [Phase 0 of compound (DCI): SAR126119] THR-2010-01 trial Double blind, placebo controlled, escalating single-dose, pilot study to assess the safety and efficacy of THR-18 when administered to patients suffering acute ischemic stroke and treated with tPA. N° EudraCT: 2011-005317-37 PREDICT Study Prediction of Stroke-associated Pneumonia (PREDICT). Clinical Trials.gov Identifier: NCT01079728 STRAWINSKI Study Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients. ClinicalTrials.gov Identifier: NCT01264549 National Coordinator A multicenter, double-blind, placebo-controlled, randomized, parallel group study to evaluate the safety and efficacy of IV natalizumab (BG00002) on reducing infarct volume in acute ischemic stroke (101SK201) Principal Investigator and promotor MISTICS: Markers of Inflammation after Simvastatin and Triflusal for Ischemic Cortical Stroke. Multicenter, randomized, double-blind, pilot clinical trial, to compare the safety and efficacy of simvastatin, in association to aspirin or triflusal, for treatment of acute stroke, using a combination of clinical and biological end-points. STARS trial: Stroke Treatment using Acute Reperfusion and Simvastatin http://www.strokecenter.org/trials/TrialDetail.aspx?tid=1067 GRECAS: Genotyping Risk and Efficacy of Clopidogrel or Aspirin following Stroke; Towards a Personalized Secondary Prevention.


46

INTELECTUAL PROPERTY AND PATENTS 1.- “DIFFERENTIAL DIAGNOSTIC BIOMARKERS OF STROKE MIMICKING CONDITIONS AND METHODS OF USE THEREOF”. Inventors: Joan Montaner. Application number: WO2009EP62071 20090917 Priority number(s): EP20080164495 20080917 2.- “METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF HEMORRHAGIC TRANSFORMATION” Inventors: Mar Hernández-Guillamón, Mercedes Unzeta and Joan Montaner. Application number: EP20090811142 20090902 Priority number(s): WO2009ES70362 20090902; ES20080002548 20080903 3.- “METHODS USING LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN AN ACUTE CARE SETTING” Inventors: Pilar Delgado and Joan Montaner Application number: WO2011US34728 20110502 Priority number(s): US20100330193P 20100430 4.- “METHOD OF PREDICTING THE EVOLUTION OF A PATIENT SUFFERING OF A NEUROVASCULAR DISEASE” Inventors: Miram Navarro, Anna Rosell and Joan Montaner. EP11382047 5.- "ENDOTHELIAL PROGENITOR CELLS LABELLED WITH SUPERPARAMAGNETIC IRON OXIDE MICRO AND NANOPARTICLES IN CEREBROVASCULAR DISORDERS, PROCESS FOR THEIR PREPARATION AND USES THEREOF". Inventors: Anna Roig, Anna Rosell and Joan Montaner. nº EP 11382104.5

joan montaner villalonga - ibis: instituto de … · curriculum vitae, joan montaner villalonga 5...

Documents